PUNE CANCER REGISTRY DIVISION OF THE MUMBAI CANCER REGISTRY

CANCER INCIDENCE AND MORTALITY IN PUNE CITY 2006-2010

INDIAN CANCER SOCIETY MUMBAI, INDIA.

PUNE CANCER REGISTRY DIVISON OF THE BOMBAY CANCER REGISTRY

CANCER INCIDENCE AND MORTALITY IN PUNE CITY 2006-2010

Dr.Purvish Parikh

Principal Investigator Pune Cancer Registry Indian Cancer Society

Ms.S.S.Koyande

Executive In-Charge & Co-Principal Investigator Pune cancer Registry Indian Cancer Society Mumbai, India

Dr.P.S.Adhav

Hon. Secretary
Pune Cancer Registry
Indian Cancer Society
B.J.Medical College and Hospital
Pune, India

Dr.Kalpana Kulkarni

Hon.Joint Secretary
Pune Cancer Registry
Indian Cancer Society
B.J.Medical College and Hospital
Pune, India

Acknowledgements

The Pune Cancer Registry Division of the Mumbai Caner Registry became operative in January 1972 as a collaborative effort with the B.J.Medical College, Pune. The staff members of the department of Preventive and Social Medicine at the medical college were entrusted with the day-to-day work relating to the registry.

This publication the ninth issue in the series "Cancer Morbidity and Mortality in the Pune City Agglomeration" and is based on all new cancer cases diagnosed in the resident population of Pune City during the 5-years period, 1st January 2006 to 31st December 2010.

We are grateful to the administration and staff members of various hospitals and consultants in private practice in Pune and Mumbai, without whose cooperation our efforts to register all the resident cancer cases in Pune, would not have succeeded. The executive Health Officer of the Pune Municipal Corporation deserves the special mention and we sincerely thank him, for making the death records of the city population freely available to us. We also wish to thank the Director of Census Operations of the Maharashtra State, for supplying us with the population breakdown according to age, sex and religion for Pune city. We are indebted to the Dean of the Sassoon Hospital, Pune, for permitting us to examine the medical records of the hospital and providing adequate office space for our staff members.

Dr.Purvish Parikh Mrs.Shravani Koyande Dr.P.S.Adhav Dr.Kalpana Kulkarni

STAFF OF PUNE CANCER REGISTRY

(As on 01.01.2013)

Medical Social Investigators

Mrs. N. S. Shaikh

M.S.W.

Mrs.S. Kochure,

M.S.W.

Research Assistant

Mrs.V.V.Jahagirdar B.A.

Contents

No	Name	Page
1	Introduction	7
2	Demographic Characteristics of Pune City Agglomeration	7
3	Population Estimates	8
4	Cancer Registration System	8
5	Working of the Registry	9
6	Sources of Data	10
7	Cancer Incidence Reporting System	10
8	Results Site Age Method of Diagnosis Religion Histology	10 11 11 15 16 18
9	Mortality	18

List of Tables

No	Name	Page
1	Estimated resident population by age and sex, as on 1 st July 2008 (Mid point of the period 2006-2010), Pune City Agglomeration, Total Population (All religious community)	22
2.	Estimated Resident population by religion and sex, as on 1 st July 2008 (Mid point of the period 2006-2010), Pune City Agglomeration	22
3	Incident cases of cancer by source and year of registration, with percentages, Males, Pune City Agglomeration, 2006-2010	23
4	Incident cases of cancer by source and year of registration, with percentages, Females, Pune City Agglomeration, 2006-2010	23
5	Number of Incident cases of cancer by site group (ICD-10) and year of registration with percentages, Pune City Agglomeration, Male, 2006-2010	24
6	Number of Incident cases of cancer by site group (ICD-10) and year of registration with percentages, Pune City Agglomeration, Female, 2006-2010	24
7	Number of Incident cases of cancer by site (ICD-10) and age with percentages, Pune City Agglomeration, Male, 2006-2010.	25
8	Number of Incident cases of cancer by site (ICD-10) and age with percentages, Pune City Agglomeration, Female, 2006-2010.	26
9	Average Annual age-specific, World age-adjusted and truncated (35-64 years) incidence rates of newly diagnosed cancer cases per 100,000 persons Pune City Agglomeration, Male, 2006-2010.	27
10	Average Annual age-specific, World age-adjusted and truncated (35-64 years) incidence rates of newly diagnosed cancer cases per 100,000 persons Pune City Agglomeration, Female, 2006-2010.	28
11	Incident cases of cancer by site (ICD-10) and Method of Diagnosis with percentages, Pune City Agglomeration, Male, 2006-2010.	29
12	Incident cases of cancer by site (ICD-10) and Method of Diagnosis with percentages, Pune City Agglomeration, Female, 2006-2010.	30
13	Incident cases of cancer by site (ICD-10) and Religion with percentages, Pune City Agglomeration, Male, 2006-2010.	31
14	Incident cases of cancer by site (ICD-10) and Religion with percentages, Pune City Agglomeration, Female, 2006-2010.	32
15	Number of Histologically proved incident cases of histology and sex with percentages, Pune City Agglomeration, 2006-2010.	33
16	Number of cancer deaths by age and site (ICD-10), with percentages (Death in Period), Male, Pune City Agglomeration, 2006-2010.	34
17	Number of cancer deaths by age and site (ICD-10), with percentages (Death in Period), Female, Pune City Agglomeration, 2006-2010.	35
18	Age-specific, world age-adjusted and truncated (35-64 years) death rate per 100,000 persons, Male, Pune City Agglomeration, 2006-2010.	36
19	Age-specific, world age-adjusted and truncated (35-64 years) death rate per 100,000 persons, Female, Pune City Agglomeration, 2006-2010.	37

Introduction

This is the 9th publication in the series "Cancer Morbidity and Mortality in Pune City Agglomeration". In this publication the new cancer cases diagnosed among the residents of Pune City Agglomeration during the period, 2006-2010 are analyzed and presented.

Demographic Characteristics of Pune City Agglomeration

Pune is one of the important district of Maharashtra State which lies on a plateau between latitude 17^o54' and 19^o22' North, and longitude 70^o24' and 75^o14' East. It has a dry and invigorating climate due to its altitude (500 meters above sea level) and the prevalence of westerly breezes. It's soil is free from alluvial deposits. The lowest temperature reached, is 5^oC during January and February while the maximum goes up to 35^oC in May. The main precipitation occurs during the southwest monsoon, which begins by the middle of June and extends up to the middle of October. The average annual rainfall is approximately 900mms. Pune receives it's water supply from 'Khadakwasla', a storage dam nearby.

The area and population by sex, for each town in the Pune City Agglomeration by 2001 census is presented in Table A. The Pune district covers an area of approximately 15,643 sq.kms. It supports a population of 5.51 millions, which gives a density of 352 persons per sq.kms. Of these, 2.80 million (about 50.9%) reside in urban areas. Of the total urban spread, Pune City Agglomeration alone covers 344.18 sq.kms. having a population of 3.55 million (2001 census). The agglomeration comprises Pune City, the Pimpri Chinchwad area, the Pune Cantonment, the Kirkee Cantonment, the Dehu Road Cantonment, Hadapsar, Lohagaon, Khadakwasala and Dehu.

Pune City has a historic past, as it was the capital in the Post-Moghul era of the Maratha Kingdom of Shivaji and the Peshwas. It is renowned for its educational facilities, since the early part of the 20th century. It is also the administrative head quarters of the district. Medical and educational facilities are available in ample measure, and many important industries have been established around this region, since 1950s.

Table A: Area and Population by Sex, for each town in the Pune City Agglomeration, 2001.								
Name of Town	Area in Kms	Population						
		Male	Female	Total				
Pune City	138.76	1321338	1217135	2538473				
Pimpri-Chinchwad	64.81	547050	465422	1012472				
Pune Cantonment	13.88	41241	38724	79965				
Kirkee Cantonment	13.23	43386	34087	77473				
Dehu Road Cantonment	36.00	24855	22066	46921				
Dehu	13.25	2751	2581	5332				
Pune City Agglomeration	344.18	1980621	1780015	3760636				

The Pune City Agglomeration consists of a multi-religious group, of which according to the 2001 Census 79.70% were Hindus, 8.89% were Muslims, 2.64% were Christians, 5.75% were Neo-Buddhists, 2.20% were Jains. The Pune City Agglomeration has 45% of the District, the sex ratio being 900 females per 1000 males. The population density is 10330 per sq.kms.

The majority of hospitals in Pune are maintained either by the Municipal Corporation, the State Government or public Trusts. There are three medical colleges in the area, viz., the B.J.Medical College, associated with the Sassoon General Hospital, the Armed Forces Medical College with the Command Hospital, and the B.A.M.S.College with the Seth Tarachand Hospital.


There are 142 other independent hospitals, 15 Health Centers, 10 Nursing Homes and 1095 Dispensaries in the survey zone. The diagnosis and treatment of cancer is however, centralized in six major hospitals and nursing homes, viz., the Sassoon General Hospital, the K.E.M. Hospital, the Lata Mangeshkar Hospital, the Ruby Hall Nursing Home, the Jahangir Nursing Home, the Inlaks Badhwari Hospital and the Armed Forces Command Hospital. Major cancer surgery is undertaken at all these institutes. Facilities for Cobalt 60 beam therapy are however available at Ruby Hall Nursing Home, Inlaks Budharani Hospital and the armed Forces Command Hospital.

Population Estimates

The Pune City Agglomeration included Pune city, Pune Cantonment, Kirkee Cantonment, Dehu Road Cantonment, Khadakwasla, Dehu Road, Lohagaon and The Pimpri Chinchwad New Township.

The base population was estimated from the 1991 and 2001 census reports of Maharashtra State. The population of Pune Agglomeration as on 1st July 2008, the midpoint of the period under the review (2006-2010), is estimated by "Distribution Method" by 5 year age and sex, using the 1991 and 2001 census figures.

The estimated population of the Pune City Agglomeration, as on 1st July 2008 (the midpoint of the period 2006-2010) is 3.93 million (2.07 million males and 1.86 million females). Population distribution by age and sex for Pune City Agglomeration for the year 2008 is shown in the age-pyramid (Fig-1). The estimated population by age and sex is given in Table 1, and by religion and sex in Table 2.



Percentage Distribution of estimated Resident Population of Pune City as on 1st July 2008.

Cancer Registration System

Population based cancer registration is a procedure evolved to obtain detailed information on all persons affected by the disease who are resident within a precisely defined geographical area, which can be pooled and analyzed at a centralized repository. Such a registry differs in many ways from a survey, wherein similar information is obtained only as a spot check, during a select period of time, which can thus reveal only the prevalence of a disease, at a given time. The collection of factual information on the other hand is a continuous process in a registry setup, where efforts are made to obtain the necessary information, as soon as possible after diagnosis has been made.

During the period 2006-2010, information was obtained from all cancer patients registered in hospitals, under the care of consultants, physicians, surgeons, gynecologists and radiologists in Pune City and from Pune residents under treatment at the Tata Memorial and other leading hospitals in near-by Bombay City. General medical practitioners are not contacted individually, because according to local practice only medical specialists treat cancer patients in hospitals and nursing homes and even those

patients not admitted for hospital care are at one stage or the other referred to such specialists by the general practitioners. The death records maintained by the Pune Municipal Corporation provide a means for checking on any missed cases.

Working of the Registry

Staff members personally visit the wards of the co-operating hospitals regularly; to interview all confirmed cancer patients and also those who are under cancer investigation. The record files maintained by the various departments of these hospitals viz. Pathology, Hematology, Radiology and the various registers in the specialized surgical and medical wards, are also examined.

The requisite details obtained for each patient, are cross-checked with the information collected from the various departments of the collaborating hospitals, to ensure completeness of records. Full information on every cancer patient registered at each and every hospital is thus obtained, irrespective of whether or not the patient is subsequently treated at the particular hospital. Additional information is obtained every time a cancer patient is re-admitted or re-examined at the institution.

As a result of such data collection from different hospitals. One and the same patient is sometimes found to be registered at two or more hospitals. Care is taken, to see that multiple entries for the same patient are not made in our records. On the other hand in some instances complete medical information is obtained by combining the data obtained from two or more hospitals, of one and the same patient.

Supplementary information can often be gleaned from the death records maintained by the Vital Statistics Division of the Pune Municipal Corporation. Copies are made of all death certificates, which mention cancer or tumor as the cause of death. These death certificates are then matched against the registered cases in our files. Every cancer death not traceable to an entry in our files, is labeled as an "unmatched death" and the date of death is then taken as the date of first diagnosis, and is so registered in the corresponding year's data file. Furthermore copies of all death certificates where the term 'Cancer' or 'Tumor' is mentioned as the cause of death are individually scrutinized to confirm the statement.

Only patients residing in Pune City and suburbs are included in the register so that the information collected could be related to a known population at risk. Non-residents, whose residence cannot be specifically confirmed, are also not included in the study.

After collecting the necessary information from the various collaborating institutes, the proforma sheets are classified into three groups, resident, non-resident and residence not known. Non-resident cases are filed site-wise and sex-wise. If the cancer patient whose duration of residence is not known, is found enrolled in the electoral rolls, he is considered as a resident. All other cases whose duration of residence is not known, are filed alphabetically. The resident cases are cross checked with the cards of the alphabetic index. Previously reported cases were edited and the new cases were registered and filed according to the site of cancer, the sex of the patient and the registration number.

Copies of the death certificates, from the Vital Statistics Department of the Municipal Corporation are classified according to residential criteria. Non-resident cases are filed alphabetically, as per cause of death and sex. Resident cases are checked with the alphabetic index. Unmatched cases are registered in the morbidity files. All deaths (matched and unmatched) are entered separately in the corresponding years death files, and are filed numerically by sex and cause of death.

Sources of Data

Two major sources have been utilized for cancer data collection.

- All hospitals, nursing homes and consultants in private practice in the registry area.
- The Vital Statistics Division of the Department of Public Health of the Pune Municipal Corporation.

Cancer Incidence Reporting System

Cancer Incidence is defined as the occurrence of new cancer cases in a defined population during a specified time period. For the purpose of this report, 2006-2010 incidence is based on those cancers registered and which were first diagnosed between 1st January 2006 and 31st December 2010 from residents of Pune City Agglomeration.

All malignant tumors including those where the pathologist may merely suspected malignant changes are registered. Cases under code 'O' (Benign) or '1' (uncertain whether benign or malignant borderline malignancy) or '2' (carcinoma in situ) are not included in our files. Cancer cases where the death certificate is the only source of information, are however included. Patients, in whom cancer has been ruled out or has not yet been diagnosed, are also omitted from our register.


We utilize the coding system devised by the World Health Organization using code numbers C00-C95 as published in the Manual of the International classification of Diseases, Injuries and Causes of Death (10th revision of 1990).

For histology coding, the World Health Organization's 2002 edition of International Classification of Diseases for Oncology (ICD-O) giving histogenic and malignancy codes is followed, in conjunction with the primary site codes suggested by the World Health Organization.

Results

During the period under review (2006-2010), 14308 new cancer cases were registered among residents of Pune, which gives an average of 2861 new cases per annum. Of these 14308 new cases, 6831 were males and 7477 were females indicating a M/F sex ratio 0.91:1.0 which is somewhat reverse of the M/F sex ratio in the general population is 1.11:1.0

The number of new cases by year and sources of registration which percentage distribution for males and females are presented in Table 3 and 4 respectively. Out of the 14308 new cancer cases, 13428 were registered through collaborating hospitals and 880 were registered from Municipal Corporation files. More than 55% of the cases are registered at 4 major sources Ruby Hall Nursing Home (3146), Sassoon General Hospital (1707), King Edward Hospital (714), and Inlack Budharani (2340). The number of incident cases by year and sex is shown in Fig.2



NUMBER OF INCIDENT CASES OF CANCER BY SEX AND YEAR OF REGISTRATION

TABLE B: NUMBER OF NEW CANCER CASES BY SITEGROUP AND SEX WITH PERCENTAGE								
DISTRIBUTION, PUNE CITY 2006-2010.								
SITE GROUP	MAI	LE	FEMA	LE	TOT	AL		
	CASES	%	CASES	%	CASES	%		
Buccal Cavity & Pharynx	1287	18.8	599	8.0	1886	13.2		
Digestive Organs	1842	27.0	1132	15.1	2974	20.8		
Respiratory Organs	940	13.8	369	4.9	1309	9.1		
Bone, C.Tissue, Skin, & Breast	359	5.3	2437	32.6	2796	19.5		
Genital Organs	674	9.9	1906	25.5	2580	18.0		
Urinary Organs	381	5.6	147	2.0	528	3.7		
Eye, Brain, Thyroid & Secondary	663	9.7	489	6.5	1152	8.1		
Lymphomas & Leukemias	685	10.0	398	5.3	1083	7.6		
Total	6831	100.0	7477	100.0	14308	100.0		


The percentage distribution of new cancer cases diagnosed during 2006-2010, by site-group and year of registration for males and females is presented in Table 5 and 6 respectively. In males, the digestive system is found to be most commonest cancer site group followed by buccal mucossa and respiratory organs in each year. In females, breast ranked first followed by genital organs and digestive system. Total number of cancer cases has been gradually increased each year from 2006 to 2010, except in 2009 and then it has been dropped slightly in both the sexes.

Age

The number of new cancer cases by site and age are presented in Table 7 & 8 for the period 2006-2010, for males and females respectively. The current distribution of the resident population and the new cancer cases by broad age groups and sex for the period 2006-2010 is presented in Table C.

TABLE C: PERCENTAGE DISTRIBUTION OF THE RESIDENT POPULATION AND NEW CANCER CASES										
BY AGE AND SEX	BY AGE AND SEX, PUNE CITY 2006-2010.									
AGE GROUP		POPULATION	J	NEW CANCER CASES						
	MALE	FEMALE	TOTAL	MALE	FEMALE	TOTAL				
00-14	13.9	12.5	26.4	1.1	0.8	1.9				
15-34	21.9	18.7	40.6	3.6	3.5	7.1				
35-64	14.8	13.6	28.4	23.2	31.8	55.0				
65+	2.2	2.5	4.7	19.8	16.3	36.1				
TOTAL	52.7	47.3	100.0	47.7	52.3	100.0				

This clearly indicates that cancer occurs mostly at older ages, as only 1.9% of the total number of cancer cases registered, were under 15 years of age, although this age group accounts for 26.4% of the total population in the Agglomeration. The association of cancer with the aging process is clearly shown by the fact that 36.1% of the cases were diagnosed in those aged 65 and above, an age group which comprises only 4.7% of the population (Fig 3).



PERCENTAGE DISTRIBUTION OF THE RESIDENT POPULATION AND CANCER CASES


Average annual age-specific, crude, age-adjusted and truncated incidence rates by site, are given in Table 9 & 10 for males and females respectively.

By relating the average annual incidence to the estimated resident population of Pune City Agglomeration as on 1st January 2001 (mid point of the period 2006-2010), we find a crude cancer incidence rate of 58.6 per 100,000 population. The crude cancer incidence rate for females (64.8) was found to be higher by 12% than that for males (53.1).

Average annual age-specific incidence rates per 100,000 population for all cancer sites together by sex, for the period 2006-2010 are presented in Table D.

TABLE D: AVERAGE ANNUAL AGE SPECIFIC INCIDENCE RATES PER									
100,000 POPULATION FO	100,000 POPULATION FOR ALL CANCER SITES, BY SEX, 2006-2010								
AGE-GROUP	MALE	FEMALE							
00-04	3.5	3.0							
05-09	7.3	4.1							
10-14	3.5	3.7							
15-19	5.7	3.7							
20-24	6.0	6.5							
25-29	10.0	12.6							
30-34	19.2	21.9							
35-39	31.1	45.0							
40-44	43.5	86.2							
45-49	65.6	123.9							
50-54	111.9	193.8							
55-59	211.4	286.0							
60-64	312.5	323.5							
65-69	419.4	309.7							
70-74	476.0	373.5							
75+	722.0	489.3							
TOTAL	53.1	64.8							

Cancer incidence rates were found to be increase sharply with age. The curves for men and women however were quite distinct. At the younger ages the incidence rates were found to be somewhat higher in males. Age-specific incidence rates were higher in females only between the age 25 to 64. The frequent occurrence of cancers involving the female genital organs and the breast, perhaps accounts for most of the differences noted between male and female rates, between the ages 25 to 64. Around the age of 65, the incidence curves for men and women intersect, the high incidence rates for the older males and perhaps primarily due to the high incidence of prostate, lung, oesophagus, stomach and larynx cancers (Fig.4).




AGE SPECIFIC INCIDENCE RATES PER 100,000 POPULATION, FOR ALL CANCER SITES

Since the incidence of cancer is known to increase with age, comparison of the rates between different populations, should take into consideration the age composition of each group. The commonly accepted method of minimizing the difference in age distribution of the incidence rates is to base the rates to be compared, on a common age distribution. Cancer incidence rates adjusted to the age distribution, of the population of the World taken as a whole, indicated that the age-adjusted incidence rate of cancers in men at 84.4 is somewhat lower than that in women at 95.5

The most common sites of cancer based on age-adjusted incidence rates in males and females are shown in Table E. In males, prostate being the leading site with the mouth coming second in rank. Lung ranks third and larynx ranks fourth in men. Cancers of the breast are found to be predominant in females, the breast being the leading site with cervix coming second in rank. The ovary ranks third and mouth ranks fourth in women (Fig.5).

	TABLE E: AVERAGE ANNUAL AGE-ADJUSTED INCIDENCE RATES BY SEX PER 100,000 POPULATION								
AT TEN	AT TEN LEADING SITE AND AT ALL SITE, 2006-2010								
		MALE				FEMALE			
RANK	ICD10	SITE	AAR	RANK	ICD10	SITE	AAR		
1	C61	Prostate	7.3	1	C50	Breast	23.6		
2	C03-06	Mouth	7.2	2	C53	Cervix	11.3		
3	C34	Lung	5.6	3	C56	Ovary	5.2		
4	C32	Larynx	4.7	4	C03-06	Mouth	3.8		
5	C16	Oesophagus	4.7	5	C15	Oesophagus	3.2		
6	C81-C85	Lymphoma	4.0	6	C54	Corpus Uteri	3.0		
7	C16	Stomach	3.6	7	C34	Lung	2.8		
8	C22	Liver	3.5	8	C19-21	Rectum	2.2		
9	C19-21	Rectum	3.3	9	C81-85	Lymphoma	2.1		
10	C01-02	Tongue	3.2	10	C18	Colon	2.0		
AAR AT ALL SITES			75.9	AAR A	Γ ALL SITE	S	80.2		




AGE ADJSUTED INCIDENCE RATES PER 100,000 POPULATION AT TEN LEADING SITES, 2006-2010.


Age reporting was found to be more reliable in the age group 35-64. The truncated incidence rates between the age 35 to 64 adjusted to the age distribution of the world population, are presented in Table F, where ten leading cancer sites ranked as per truncated rates for males and females are given (Fig. 6).

TABLE F: THE LEADING CANCER SITES BY TRUNCATED (35-64) INCIDENCE RATES PER								
100,000 POPULATIN BY SEX, 2006-2010.								
	1	MALE			F	EMALE		
RANK	ICD10	SITE	TR	RANK	ICD10	SITE	TR	
1	C03-06	Mouth	15.1	1	C50	Breast	52.4	
2	C34	Lung	7.9	2	C53	Cervix	26.7	
3	C32	Larynx	7.5	3	C56	Ovary	10.1	
4	C01-02	Tongue	6.5	4	C03-C06	Mouth	7.9	
5	C15	Oesophagus	6.3	5	C54	Corpus Uteri	6.1	
6	C81-85	Lymphoma	5.7	6	C34	Lung	5.3	
6	C16	Stomach	5.4	7	C15	Oesophagus	5.0	
8	C19-21	Rectum	5.3	8	C19-21	Rectum	4.1	
9	C71	Brain	5.0	9	C01-02	Tongue	3.4	
9	C61	Prostate	4.8	10	C81-85	Lymphoma	3.4	
TR AT A	ALL SITES		112.8	TR AT A	LL SITES		159.3	

In males, the age group 35-64, cancer of the mouth rank first followed by cancer of the lung, larynx, and tongue in descending order. In females in the age-group 35-64, cancer of the breast ranks first followed by cancer of the cervix, ovary and mouth in descending order.

The highest incidence rates at different age groups by primary site in males and females are presented in Table G. In children, both in males and females, leukemias were found to be predominant. In males, in the age group 35-64, other-mouth was most frequent site and above the age of 65, those were cancers of the prostate. In females, breast was the most frequent site of cancer above the age of 20.






TRUNCATED INCIDENCE RATES PER 100,000 POPULATION AT TEN LEADING SITE, 2006-2010

TABLE G: TE	IE HIGHEST INCIDENCE	RATE BY A	GE AND SEX PER 100.00	00 POPULATION.
2006-2010.	E MONEST MODERCE		OE THIS BEHT TER 100,00	50 T OT CENTION,
AGE GROUP	MALE		FEMAL	E
	SITE	RATE	SITE	RATE
00-04	Leukemias	1.0	Leukemias	0.9
05-09	Leukemias	2.9	Leukemias	1.3
10-14	Leukemias	1.2	Leukemias	0.9
15-19	Lymphoma	1.2	Leukemias	0.7
20-24	Brain	0.9	Breast	0.6
25-29	Brain	1.8	Breast	3.0
30-34	Tongue	2.5	Breast	7.4
35-39	Mouth	3.7	Breast	14.2
40-44	Mouth	8.1	Breast	33.1
45-49	Mouth	10.5	Breast	47.9
50-54	Mouth	14.7	Breast	64.7
55-59	Mouth	26.6	Breast	90.6
60-64	Mouth	38.4	Breast	91.5
65-69	Prostate	41.1	Breast	82.6
70-74	Prostate	71.9	Breast	84.6
75+	Prostate	154.9	Breast	120.6
ALL AGES	Mouth	5.0	Breast	19.2

Method of Diagnosis

An evaluation of the reliability of cancer data is usually measured by the percentage of patients having microscopic proof of diagnosis as compared with other methods which are considered less accurate. The percentage of new cancer cases diagnosed by method of diagnosis and sex is presented in Table H. During the period 2006-2010, 87.3% of the new cases recorded had microscopic confirmation of cancer. The percentage of patients diagnosed on the basis of clinical investigation was 1% and clinical alone was 5.5% and 6.2% of cases were registered from death certificates alone. The number of new cancer cases by site and method of diagnosis for males and females are presented in Table 11 and 12 respectively. The percentage distribution of the cases according to method of diagnosis is shown in Fig 7.






Fig. 7 PERCENTAGE DISTRIBUTION OF THE INCIDENT CASES OF CANCER BY METHOD OF DIAGNOSIS, $2006\mbox{-}2010$

The percentage of patients having microscopic confirmation of cancer, depends primarily on the accessibility of the part affected. Histological confirmation of cancers arising in the buccal arising in the buccal cavity, pharynx and the female genital tract are thus usually available with greater frequency than for tumors at inaccessible sites, such as the digestive and respiratory systems.

About 6.2% of cancer cases were registered through death certificates alone. This figure is considerably lower than in the previous years, which indicates the improvement in the coverage of the sources. Most probably these were patients with advanced disease who attended out-patient departments of various collaborating hospitals to seek medical advice at a late stage, when no active treatment was possible.

TABLE H: THE PERCENTAGE OF NEW CANCER CASES DIAGNOSED, BY METHOD OF DIAGNOSIS, 2006-2010								
METHOD OF DAGNOSIS	MALE		FEM	ALE	TOTAL			
	CASES	%	CASES	%	CASES	%		
MICROSCOPIC	5906	86.5	6586	88.1	12492	87.3		
CLINICAL INVESTIGATION	91	1.3	58	0.8	149	1.0		
CLINICAL	415	6.1	372	5.0	787	5.5		
DCO	419	6.1	461	6.2	880	6.2		
TOTAL	6831	100.0	7477	100.0	14308	100.0		

Religion

Considerable variation was noted in the incidence of cancer at various sites in both the sexes, in patients having their domicile in the countries and in those professing different religious faiths within a particular population, due to a variety of causes mainly endocrine, dietary or environmental. Such variations call for adequate investigations, to elucidate the complex etiology of the disease. To study the differences in cancer incidence by religion, the crude rates by religion and sex are presented in Table I. From this table it is evident that different religious groups in Pune City Agglomeration exhibit considerable variation in the total incidence of cancer in each sex.

TABLE I: CRUDE INCIDENCE RATES BY RELIGION AND SEX, 2006-2010					
RELIGION	MALE	FEMALE			
HINDU	57.3	71.5			
MUSLIM	54.5	52.1			
CHRISTIAN	56.8	51.7			
OTHERS	12.6	19.2			
TOTAL	53.1	64.8			

The different groups are distinguished from each other by their habits, customs and socio-economic status. Thus, even though living in the same environment, they present striking differences from each other, in the relative frequency with which cancer

occurs at various sites. An appraisal of this situation was this considered promising, in order to study the differences in site patterns of incidence. In order to define the magnitude and nature of the differences observed, the number of cancer cases and the percentage distribution of new cases in each religious group by site, are presented in Table 13 and 14 for males and females respectively.




Fig.8 CRUDE INCIDENE RATES BY RELIGION, 2006-2010.

The site incidence patterns exhibit considerable differences in the various religious groups. The most common cancer sites in each religious group by sex are presented in Table J.

TABLE J: FIVE	E MOST C	OMMON SITES OF CANCER IN	DIFFER	ENT REL	IGIOUS GROUPS BY SEX 2006-2	010		
RELIGION		MALE			FEMALE			
	RANK	SITE	%	RANK	SITE	%		
HINDU	1	Mouth	5.7	1	Breast	21.0		
	2	Prostate	4.8	2	Cervix	10.4		
	3	Lung	3.9	3	Ovary	4.7		
	4	Oesophagus	3.4	4	Mouth	3.2		
	5	Lymphoma	3.4	5	Oesophagus	2.8		
MUSLIMS	1	Mouth	5.5	1	Breast	16.4		
	2	Prostate	4.1	2	Cervix	6.0		
	3	Lung	4.1	3	Ovary	3.3		
	4	Stomach	2.8	4	Corpus Uteri	2.6		
	5	U.Bladder	2.8	5	Lung	2.2		
CHRISTIAN	1	Prostate	6.2	1	Breast	19.0		
	2	Lung	5.9	2	Cervix	5.5		
	3	Oesophagus	4.1	3	Corpus Uteri	3.8		
	3	Lymphoma	3.0	4	Ovary	3.4		
	3	U.Bladder	2.9	5	Brain	1.7		

Among males, in Hindus and Muslims, the Mouth is the leading site of cancer, and Prostate is the leading in Christians. The Prostate is the second leading in Hindus and Muslims and lung ranks second in Christians. Among females, in Hindus, Muslims and Christians the breast is the leading site followed by the cervix.

Histology

During the period 2006-2010, a total of 12492 cancer cases were confirmed microscopically, so that the proportion of histopathologically proved cases was found to be 87.3%. The various histological varieties observed in the Pune city Agglomeration for the period 2006-2010, by sex with percentage distribution is presented in Table 15.

Papillary and squamous cell neoplasms are found to be the commonest histological type constituting about 27% of the total number of the histologically proved cases. This is the most common variety affecting in both males and females. The next common variety affecting males is adenocarcinomas and in females are ductal, lobular and medullary neoplasms and adenocarcinomas.

The distribution of histologically proved cases by site-groups and sex is present in Table 16.

Mortality

Mortality statistics have an impressive history as a useful tool for undertaking epidemiological studies of cancer. The mortality analysis of various occupational groups has provided the evidence, which lead to the discovery of several chemical carcinogens. Examination of time trends of the death rates, has in turn lead to the development of new etiologic hypotheses. Furthermore, international comparison of mortality data has been productive in outlining new directions for undertaking epidemiological field studies.

The significant role played by mortality data in epidemiological studies, in the past, was largely due to the unavailability of morbidity data, which is considered more valuable for undertaking epidemiological investigations. Gradually, the role of mortality studies has diminished with the establishment of population based cancer registries in various countries throughout the world and the availability of adequate morbidity data. The value of mortality data has also decreased with the increasing use of epidemiological field studies undertaken to test specific etiologic hypothesis, developed as a result of analysis of mortality statistics.

At our registry, mortality data has been obtained from the death records maintained by the vital statistical division of the Pune Municipal Corporation. Copies are made by us of all death certificates, which mention the worlds 'Cancer' or 'Tumor' as being the cause of death.

The total 5563 number of cancer deaths by age and the cause of death for the period 2006-2010, are presented in Tables 17 and 18 for males and females respectively. The age-specific, crude, age-adjusted and truncated mortality rates, are presented in Table 19 and 20, for males and females respectively. The average age-adjusted death rates at all sites, were found to be 31.9 for males and 30.8 for females per 100,000 populations.

The leading sites of cancer deaths, ranked by age-adjusted rates in males and females, are given in Table K. Deaths from cancers of the lung, top the list in males, followed by deaths from cancers involving the oesophagus, stomach and prostate. Deaths from cancers of the breast, top the list in females, followed by deaths from cancers involving the oesophagus, cervix and ovary (Fig.9)

TABLE K: AVERAGE ANNUAL AGE ADJUSTED CANCER DEATH RATES PER 100,000 POPULATION AT ALL STIES AND THE LEADING SITES, 2006-2010													
MALE	TOTOLITTON THE TALL	31112371111	FEMALE										
RANK	SITE	AAR	RANK	SITE	AAR								
1	Lung	3.2	1	Breast	7.5								
2	Prostate	2.9	2	Cervix	3.0								
3	Oesophagus	2.6	3	Ovary	2.8								
3	Liver	2.4	4	Lung	1.9								
5	Stomach	2.1	5	Oesophagus	1.7								
6	Mouth	2.0	6	Mouth	1.3								
6	Lymphoma	1.7	7	Leukemia	1.2								
8	Larynx	1.5	8	Colon	1.0								
9	Pancreas	1.5	9	Stomach	0.9								
10	Colon	1.4	10	Liver	0.9								
ALL SIT	TES	31.9	ALL SIT	ES	30.8								





Fig.9
AGE-ADJUSTED DEATH RATES PER 100,000 AT TEN LEADING SITES, 2006-2010

The age specific rates were found to follow the general pattern of increase with age. The age-specific death rates for females were found to be generally lower than for males, except in the age-group 30 to 69 (Table L). This can be explained by the high mortality rates of female's genital cancers that occurs in the reproductive age groups (Fig. 10).

TABLE L: AVEI	RAGE ANNUAL AGE	SPECIFIC MORTALITY
	00 POPULATIONS BY	
AGE-GROUP	MALE	FEMALE
00-04	1.3	1.0
05-09	1.8	1.3
10-14	1.1	1.0
15-19	2.3	0.9
20-24	1.2	1.7
25-29	2.7	3.2
30-34	4.6	6.1
35-39	9.6	11.9
40-44	13.5	24.9
45-49	20.7	40.0
50-54	38.1	60.0
55-59	77.1	106.4
60-64	120.2	103.0
65-69	178.6	124.4
70-74	229.5	194.8
75+	417.2	301.8
ALL AGES	21.5	24.3



 ${\it Fig. 10}$ AGE SPECIFIC MORTLAITY RATES PER 100,000 POPULATIONS, FOR ALL CACNER SITES, 2006-2010

It is important to determine whether the pattern of age and sex in cancer mortality rates, in fact reflects the incidence rates. The relative comparison of the age distribution in the mortality and morbidity analysis and the age distribution of the population by sex, are given in Table M.

TABLE M	TABLE M: RELATIVE MORBIDITY AND MORTALITY RATES OF CANCER BY SEX, 2006-2010 SEX AGE POPULATION CANCER CASES INDICATOR OF CANCER INDICATOR OF														
SEX	AGE	POPULATION	CANCER CASES	INDICATOR OF	CANCER	INDICATOR OF									
				RELAT FREQ	DEATH	RELAT FREQ									
MALE	00-14	26.4	2.3	8.7	1.7	6.3									
	15-34	41.5	7.6	18.3	5.0	12.1									
	35-60	28	48.6	173.6	41.9	149.6									
	65+	4.1	41.5	1011.9	51.4	1254.4									
FEMALE	00-14	26.4	1.5	5.5	1.2	4.5									
	15-34	39.6	6.6	16.8	4.7	11.8									
	35-60	28.8	60.8	211.1	51.8	179.9									
	65+	5.2	31.1	598.2	42.3	814.1									
TOTAL	00-14	26.4	1.9	7.0	1.4	5.4									
	15-34	40.6	7.1	17.5	4.8	11.9									
	35-60	28.4	55.0	193.6	46.9	165.1									
	65+	4.7	36.1	767.3	46.8	996.7									

Cancer incidence and mortality rates were found to be very low in the younger ages. The association of cancer incidence and mortality with the aging process, is clearly shown by the fact that the percentage of registered cancer cases and the percentage of the total number of deaths occurring in persons 65 years of age and above, are 36.1% and 46.8% respectively, as this group comprises only about 4.7% of the general population. The relative cancer incidence and mortality rates increase with age, in both the sexes. Indicators of the relative incidence and mortality, show that in the age group 00-14, the incidence rates were more or less equal in both the sexes while in the age group 15-64, the incidence rates are higher than the mortality rates but thereafter the mortality rates reach higher levels in both the sexes.

Tables

Table 1: Estimated Resident Population by Age and Sex as on 1st July 2008, Pune City, Total Population (All Religious Communities)

Age	N/L-1-		E1-		TF-4-1	1
Group	Male		Female	!	Total	
	#	%	#	%	#	%
00-04	219226	8.5	189321	8.2	408547	8.4
05-09	198974	7.7	184412	8.0	383386	7.9
10-14	260455	10.1	234719	10.2	495174	10.1
15-19	268567	10.4	219093	9.5	487660	10.0
20-24	301882	11.7	249882	10.8	551764	11.3
25-29	270199	10.5	245117	10.6	515316	10.6
30-34	226106	8.8	200550	8.7	426656	8.7
35-39	187348	7.3	184122	8.0	371470	7.6
40-44	163553	6.4	139523	6.0	303076	6.2
45-49	131383	5.1	126055	5.5	257438	5.3
50-54	111691	4.3	92052	4.0	203743	4.2
55-59	71346	2.8	64685	2.8	136031	2.8
60-64	55231	2.1	57677	2.5	112908	2.3
65-69	43779	1.7	52570	2.3	96349	2.0
70-74	30589	1.2	33573	1.5	64162	1.3
75+	32020	1.2	34664	1.5	66684	1.4
Total	2572349	52.7	2308015	47.3	4880364	100.0

Table 2: Estimated Resident Population by Religion and Sex, Pune City (As on 1st July 2008).

	Male		Femal	e	Tota	ıl
Hindu	2050062	41.96	1845632	37.88	3895694	79.82
Muslims	228653	4.68	205124	4.21	433778	8.89
Christians	67912	1.39	57981	1.19	125893	2.58
Buddhist	12703	0.26	12668	0.26	25371	0.52
Jains	148038	3.03	128629	2.64	276667	5.67
Sikhs	56675	1.16	50185	1.03	106860	2.19
Others	6351	0.13	5847	0.12	12198	0.25
Unknown	1954	0.04	1949	0.04	3903	0.08
Total	2572349	52.65	2308015	47.37	4880364	100.00

Table 3: Number of Incident Cases of Cancer by Source of Registration and Year with Percentages, Pune City, Male, 2006-10.

SOURCE	200	06	200	07	200	08	200)9	201	10	Tot	tal
	#	%	#	%	#	%	#	%	#	%	#	%
BHARATI	2	0.2	2	0.2	0	0.0	0	0.0	0	0.0	4	0.1
BOMBAY SMALL HOSP	20	1.6	6	0.5	6	0.4	11	0.8	15	1.0	58	0.8
CIPLA	97	7.7	101	7.8	90	6.4	68	5.0	61	4.1	417	6.1
DEENANATH	92	7.3	110	8.5	99	7.1	79	5.8	141	9.4	521	7.6
ESIS	10	0.8	14	1.1	0	0.0	0	0.0	1	0.1	25	0.4
INLAK	61	4.8	72	5.6	75	5.4	79	5.8	57	3.8	344	5.0
INLAK-R	158	12.5	135	10.4	135	9.6	107	7.8	119	7.9	654	9.6
JNH	57	4.5	71	5.5	72	5.1	71	5.2	56	3.7	327	4.8
JOSHI	0	0.0	0	0.0	24	1.7	28	2.0	33	2.2	85	1.2
KEM	64	5.1	61	4.7	77	5.5	71	5.2	50	3.3	323	4.7
OTHERS	7	0.6	23	1.8	0	0.0	0	0.0	0	0.0	30	0.4
PCH	1	0.1	0	0.0	1	0.1	0	0.0	0	0.0	2	0.0
PMC	77	6.1	81	6.2	74	5.3	93	6.8	92	6.1	417	6.1
PUNE	32	2.5	38	2.9	40	2.9	46	3.4	63	4.2	219	3.2
PUNE SMALL HOSP	106	8.4	79	6.1	110	7.9	84	6.1	135	9.0	514	7.5
RATNA	15	1.2	9	0.7	18	1.3	20	1.5	30	2.0	92	1.3
RHNH	160	12.7	162	12.5	198	14.1	196	14.3	190	12.6	906	13.3
RHNH-R	86	6.8	84	6.5	96	6.9	139	10.2	188	12.5	593	8.7
SANJEEVANI	0	0.0	16	1.2	17	1.2	21	1.5	1	0.1	55	0.8
SGH	162	12.8	157	12.1	172	12.3	139	10.2	178	11.8	808	11.8
ТМН	16	1.3	25	1.9	38	2.7	48	3.5	34	2.3	161	2.4
WADIA	1	0.1	2	0.2	3	0.2	0	0.0	0	0.0	6	0.1
YCMC	40	3.2	49	3.8	56	4.0	66	4.8	59	3.9	270	4.0
Total	1264	100.0	1297	100.0	1401	100.0	1366	100.0	1503	100.0	6831	100.0

Table 4: Number of Incident Cases of Cancer by Source of Registration and Year with Percentages, Pune City, Female, 2006-10.

SOURCE	2006		2007		20	08	200	09	20	10	Tot	tal
	#	%	#	%	#	%	#	%	#	%	#	%
BHARATI	1	0.1	5	0.3	4	0.3	0	0.0	0	0.0	10	0.1
BOMBAY SMALL HOSP	13	1.0	8	0.5	4	0.3	9	0.6	11	0.7	45	0.6
CIPLA	111	8.2	130	8.5	110	7.1	88	5.9	90	5.8	529	7.1
DEENANATH	94	7.0	135	8.9	88	5.7	107	7.2	171	11.0	595	8.0
ESIS	16	1.2	13	0.9	0	0.0	0	0.0	0	0.0	29	0.4
INLAK	65	4.8	94	6.2	83	5.3	83	5.6	54	3.5	379	5.1
INLAK-R	212	15.7	206	13.5	208	13.4	178	11.9	159	10.2	963	12.9
JNH	48	3.6	55	3.6	42	2.7	43	2.9	30	1.9	218	2.9
JOSHI	0	0.0	0	0.0	40	2.6	48	3.2	31	2.0	119	1.6
KEM	86	6.4	76	5.0	78	5.0	76	5.1	75	4.8	391	5.2
OTHERS	9	0.7	17	1.1	5	0.3	0	0.0	0	0.0	31	0.4
PCH	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	2	0.0
PMC	90	6.7	79	5.2	97	6.2	89	6.0	103	6.6	458	6.1
PUNE	34	2.5	41	2.7	37	2.4	45	3.0	40	2.6	197	2.6
PUNE SMALL HOSP	104	7.7	103	6.8	86	5.5	69	4.6	108	6.9	470	6.3
RATNA	13	1.0	12	0.8	10	0.6	15	1.0	11	0.7	61	0.8
RHNH	128	9.5	163	10.7	203	13.0	172	11.5	185	11.9	851	11.4
RHNH-R	101	7.5	114	7.5	174	11.2	202	13.5	205	13.2	796	10.6
SANJEEVANI	0	0.0	10	0.7	16	1.0	14	0.9	3	0.2	43	0.6
SGH	170	12.6	196	12.9	192	12.3	147	9.9	194	12.5	899	12.0
TMH	23	1.7	16	1.1	40	2.6	32	2.1	36	2.3	147	2.0
WADIA	2	0.1	1	0.1	0	0.0	0	0.0	0	0.0	3	0.0
YCMC	32	2.4	48	3.2	37	2.4	75	5.0	49	3.2	241	3.2
Total	1352	100.0	1522	100.0	1556	100.0	1492	100.0	1555	100.0	7477	100.0

Table 5: Number of Incident Cases of Cancer by Site Group and Year of Registration, with percentages, Pune City, Male, 2006-10.

SITEGROUP	200	06	20	07	20	08	20	09	20	10	To	tal
	#	%	#	%	#	%	#	%	#	%	#	%
C00-C14, Lip, Oral Cavity, & Pharynx	222	17.6	231	17.8	271	19.3	275	20.1	288	19.2	1287	18.8
C15-C26 Digestive Organs	345	27.3	351	27.1	376	26.8	385	28.2	385	25.6	1842	27.0
C30-C39 Respiratory Systems	170	13.4	210	16.2	176	12.6	183	13.4	201	13.4	940	13.8
C40-41,C45-49 Bone & Connective Tissue	38	3.0	36	2.8	45	3.2	20	1.5	39	2.6	178	2.6
C43-44 Skin	19	1.5	20	1.5	19	1.4	25	1.8	11	0.7	94	1.4
C50 Breast	15	1.2	5	0.4	11	0.8	17	1.2	39	2.6	87	1.3
C60-63 Male Genital Organs	127	10.0	123	9.5	145	10.3	128	9.4	151	10.0	674	9.9
C64-68 Urinary Oragans	71	5.6	79	6.1	63	4.5	87	6.4	81	5.4	381	5.6
C69-72 Eye & Nervous System	71	5.6	60	4.6	84	6.0	61	4.5	55	3.7	331	4.8
C73-75 Thyroid & Endocrine Glands	6	0.5	12	0.9	13	0.9	12	0.9	24	1.6	67	1.0
C76-80 Lymphonoes and Secondary Unsp	46	3.6	40	3.1	43	3.1	60	4.4	76	5.1	265	3.9
C81-90 Lymphatic System	88	7.0	85	6.6	102	7.3	78	5.7	110	7.3	463	6.8
C91-95 Leukemias	46	3.6	45	3.5	53	3.8	35	2.6	43	2.9	222	3.2
Total	1264	100.0	1297	100.0	1401	100.0	1366	100.0	1503	100.0	6831	100.0

Table 6: Number of Incident Cases of Cancer by Site Group and Year of Registration, with percentages, Pune City, Female, 2006-10

SITEGROUP	200	06	20	07	20	08	20	09	20	10	To	tal
	#	%	#	%	#	%	#	%	#	%	#	%
C00-C14, Lip, Oral Cavity, & Pharynx	109	8.1	122	8.0	139	8.9	113	7.6	116	7.5	599	8.0
C15-C26 Digestive Organs	214	15.8	237	15.6	213	13.7	235	15.8	233	15.0	1132	15.1
C30-C39 Respiratory Systems	70	5.2	89	5.8	70	4.5	68	4.6	72	4.6	369	4.9
C40-41,C45-49 Bone & Connective Tissue	31	2.3	22	1.4	33	2.1	29	1.9	24	1.5	139	1.9
C43-44 Skin	16	1.2	16	1.1	13	0.8	20	1.3	12	0.8	77	1.0
C50 Breast	362	26.8	437	28.7	469	30.1	469	31.4	484	31.1	2221	29.7
C51-58 Female Genital Organs	359	26.6	368	24.2	400	25.7	381	25.5	398	25.6	1906	25.5
C64-68 Urinary Oragans	26	1.9	29	1.9	27	1.7	27	1.8	38	2.4	147	2.0
C69-72 Eye & Nervous System	44	3.3	42	2.8	53	3.4	31	2.1	32	2.1	202	2.7
C73-75 Thyroid & Endocrine Glands	19	1.4	27	1.8	23	1.5	23	1.5	22	1.4	114	1.5
C76-80 Lymphonoes and Secondary Unsp	33	2.4	33	2.2	24	1.5	36	2.4	47	3.0	173	2.3
C81-90 Lymphatic System	37	2.7	60	3.9	58	3.7	43	2.9	51	3.3	249	3.3
C91-95 Leukemias	32	2.4	40	2.6	34	2.2	17	1.1	26	1.7	149	2.0
Total	1352	100.0	1522	100.0	1556	100.0	1492	100.0	1555	100.0	7477	100.0

Table 7: Number of Incidence Cases of Cancer by Site (ICD10 & Age), with Percentages, Pune, 2006-10, Male

ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	5	1	3	4	5	1	2	0	21	0.3
C01-02	Tongue	0	0	0	0	2	10	28	34	37	29	33	43	34	24	23	24	3	324	4.7
C03-06	Mouth	1	2	0	1	4	5	26	35	66	69	82	95	106	82	47	45	5	671	9.8
C07-08	Salivary Gland	0	1	0	0	0	2	4	2	4	2	4	4	3	8	0	4	0	38	0.6
C09-10	Oropharynx	0	0	0	0	0	1	1	2	4	5	6	13	6	8	3	14	0	63	0.9
C11	Nasopharynx	0	1	0	3	2	2	2	0	1	2	2	2	4	0	3	0	0	24	0.4
C12-13	Hypopharynx	0	0	0	0	0	1	1	4	4	3	21	17	18	13	14	24	1	121	1.8
C14	Other Oral	0	0	1	0	0	0	0	0	4	1	5	1	5	3	1	3	1	25	0.4
C15	Oesophagus	0	0	0	0	1	1	6	10	14	19	38	45	53	63	44	100	2	396	5.8
C16	Stomach	0	0	0	0	0	5	11	7	15	19	26	39	47	47	33	64	3	316	4.6
C17	Small Intestine	0	0	0	0	0	0	0	1	1	3	1	2	1	4	3	3	0	19	0.3
C18	Colon	0	0	0	4	1	5	4	8	16	18	21	30	33	34	33	52	3	262	3.8
C19-21	Retum	0	0	0	2	4	12	10	11	17	17	40	34	39	50	27	39	1	303	4.4
C22	Liver	1	0	0	0	1	2	3	7	9	17	26	30	44	45	39	69	1	294	4.3
C23-24	Gall Bladder	0	0	0	0	0	1	3	5	4	1	5	12	10	14	12	9	0	76	1.1
C25	Pancreas	0	1	0	0	2	1	0	6	4	6	22	20	37	24	16	32	1	172	2.5
C26	Oth Dig Org	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	4	0.1
C30-31	Nose, Sinuse	0	0	0	0	1	0	3	5	6	2	5	5	8	3	4	8	0	50	0.7
C32	Larynx	0	0	0	0	1	3	3	7	16	25	34	61	66	62	57	59	1	395	5.8
C33-34	Lung	0	0	0	3	3	2	8	14	15	23	58	64	55	78	63	92	1	479	7.0
C37-38	Mediastinum, Plura	0	0	0	1	0	0	0	1	1	0	5	1	3	1	03	3	0	16	0.2
C40-41	Bone	0	1	5	11	5	9	4	2	4	6	3	7	5 5	3	2	2	0	69	1.0
C40-41	Skin Melanoma	0	1	0	1	0	0	0	1	1	0	2	1	1	1	1	0	0	10	0.1
C43	Skin Others	-	0	1		7	2	-	4	3	2	9	6	14	11	7	16	0	84	1.2
		0			2	_		0			2									0.1
C47	Nervous System	0	0	1	0	1	0	0	1	0	0	0	0	1	1	0	1	0	8 10	
C48	Retroperitonium	0	0	0	0	0	2	0	1	2		1	2	1	0	1	0	0		0.1
C49	Conn & Soft Tissue	3	1	1	4	7	4	6	8	5	6	5	10	6	10	5	10	0	91	1.3
C50	Breast	0	0	0	0	1	0	5	3	6	10	11	8	8	13	11	10	1	87	1.3
C60	Penis	0	0	0	0	0	0	1	5	6	7	6	8	6	13	7	9	0	68	1.0
C61	Prostate	1	0	0	1	1	0	0	1	0	9	12	29	67	90	110	248	4	573	8.4
C62	Testis	0	0	1	1	5	9	5	2	0	3	1	0	1	0	1	3	0	32	0.5
C63	Oth Male Gen Org	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.0
C64-65	Kidney	4	3	1	0	4	2	2	8	4	13	16	22	20	26	12	19	0	156	2.3
C66-68	Urinary Bladder	1	0	0	1	1	0	4	4	8	13	16	25	31	35	29	55	2	225	3.3
C69	Eye	2	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	4	0.1
C70-72		7	21	6	14		24	27	31	19	36	23	35	20	23	17	10	1	327	4.8
C73	Thyroid	0	1	0	0	1	4	7	2	0	6	6	5	8	7	4	7	0	58	0.8
C74-75	Other Endocrine Gland	0	1		0	2	0	0	1	1	0	0	0	0	3	1	0	0	9	0.1
C76	Other III Def Sites	0	0		0	0	0	2	1	1	3	4	1	2	5	3	4	0	26	0.4
C77	Lymph Nodes	0	0	0	0	2	1	0	3	4	2	4	4	1	6	2	6	0	35	0.5
C78	Sec Resp & Dig	0	0	0	0	0	0	2	1	1	3	1	3	7	7	3	7	0	35	0.5
C79	Sec Others	0	0	0	0	1	1	0	1	2	1	2	2	4	3	2	1	0	20	0.3
C80	Unknown Primary	1	1	0	1	3	1	7	5	7	9	16	14	19	21	19	25	0	149	2.2
C81	Hodgkin Lymphoma	4	3		7	2	1	3	6	3	1	6	2	6	2	4	2	0	54	0.8
	N.H.Lymphoma	2	6	12	9	4	6	17	27	23	20	27	29	29	40	36	48	0	335	4.9
C90	Multiple Myeloma	0	0	0	0	0	0	0	2	7	2	8	8	12	14	13	8	0	74	1.1
C91	Lymphoid Leukemia	7	24	8	3	7	7	5	1	4	5	3	2	2	4	1	3	1	87	1.3
C92	Myeloid Leukemia	4	3	6	5	2	8	6	7	3	5	6	6	10	9	8	12	0	100	1.5
C93-95	Other Leukemia	0	2	1	3	0	1	1	4	3	1	2	2	6	2	5	2	0	35	0.5
Total	All Sites	38	73	46	77	91	135	217	291	356	431	625	754	863	918	728	1156	32	6831	100.0

Table 8: Number of Incidence Cases of Cancer by Site (ICD10 & Age), with Percentages, Pune, 2006-10, Female

Decoting Color	ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
Colt-02 Timpue			-																		
030-96 Mourin		•	_																		
0207-08 Salivary Cland O O O O O O O O D O D O D O O D O D O O D O		•																			
Color Colo			-										_								
Description		•																			
C12-13 Wyoppharynx			-																		
C14 Orher Oral Orher Oral Orher Oral Orher Oral Orhogous Orhagus Orhag			-												-						
C16		· · · · · · · · · · · · · · · · · · ·	-							-								_			
Stormach			-	_	-	-	-												_	-	
C17 Small Intestine			-		-	-															
C18			-		-		-	-													
Edum			0								-	-									
C22 Liver			0	0	0							-									
C23-24 Gall Bladder 0 0 0 0 0 0 1 1 3 3 3 5 7 11 11 13 9 8 2 4 0 95 1.3 C25 Pancreas 0 0 0 0 0 1 1 1 4 3 3 3 8 11 9 13 19 13 25 0 110 1.5 C25 Pancreas 0 0 0 0 0 1 1 1 4 3 3 3 8 11 9 13 19 13 25 0 110 1.5 C26 C26 Dh Dig Org 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			0	0	0	0														-	
C25 Pancreas			2	1	1	0	2	2	3	5	7	3	10			17	11				
C26 Oth Dig Org Oth Dig Org Oth Dig Org Oth Dig Org Nose, Sinuse O 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0			0	0	0	0	0	1	3	3	5	7	11	11	13	9	8		0	95	1.3
C30-31 Nose, Sinuse	C25		0	0	0				-				11	9	13						1.5
C32 Larynx	C26	Oth Dig Org	0	0	0	0	0	0	0		0		1				0				0.0
C33-34 Lung C33-34 Mediastinum, Plura 1 0 0 0 0 1 2 3 12 18 20 29 36 32 34 28 40 1 256 3.4 C37-38 Mediastinum, Plura 1 0 0 0 0 1 1 0 0 1 0 1 0 1 1 2 3 2 2 0 0 15 0.2 4 0.7 4 0.7 4 0.7 4 0.7 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C30-31	Nose, Sinuse	0	0	0	0	1	0	1	0	6	2	1	3	5	3	4	7	0	33	0.4
C37-38 Mediastinum, Plura	C32	Larynx	0	0	0	0	0	0	3	3	5	3	5	3	8	9	9	17	0	65	0.9
C40-41 Bone	C33-34	Lung	0	0	0	0	1	2	3	12	18	20	29	36	32	34	28	40	1	256	3.4
C43 Skin Melanoma 0 0 0 0 0 1 2 0 0 0 1 2 1 8 0.1 C44 Skin Others 0 0 1 0 0 3 3 3 4 6 4 7 7 7 11 13 0 669 0.9 C44 Nervous System 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 <t< td=""><td>C37-38</td><td>Mediastinum, Plura</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>1</td><td>1</td><td>2</td><td>3</td><td>2</td><td>2</td><td>0</td><td>15</td><td>0.2</td></t<>	C37-38	Mediastinum, Plura	1	0	0	0	0	1	1	0	1	0	1	1	2	3	2	2	0	15	0.2
C43 Skin Melanoma 0 0 0 0 0 1 2 0 0 0 1 2 1 8 0.1 C44 Skin Others 0 0 1 0 0 3 3 3 4 6 4 7 7 7 11 13 0 669 0.9 C44 Nervous System 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 <t< td=""><td>C40-41</td><td>Bone</td><td>1</td><td>4</td><td>10</td><td>6</td><td>6</td><td>6</td><td>0</td><td>4</td><td>0</td><td>3</td><td>4</td><td>5</td><td>1</td><td>2</td><td>2</td><td>0</td><td>0</td><td>54</td><td>0.7</td></t<>	C40-41	Bone	1	4	10	6	6	6	0	4	0	3	4	5	1	2	2	0	0	54	0.7
C44 Skin Others	C43		0	0							0		0						1	8	0.1
C47 Nervous System 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0			0																		0.9
C48 Retroperitonium			0		0						0		0								
C49		-	0										0		0						
C50 Breast D		•	-												-						
C51-52 Oth Fem Gen Org																					
C53			-																		
C54 Corpus Uteri												-	-								
C55 Uterus			-																		
C56 Ovary		•	-																		
C57-58 Oth Unsp Fem Gen Org			-																		
C64-65 Kidney		•					_														
C66-68 Urinary Bladder 0 0 1 2 0 1 1 2 1 6 9 7 10 13 20 0 73 1.00 C69 Eye 2 0 0 0 0 2 0 1 1 1 0 <t< td=""><td>_</td><td></td><td>-</td><td></td><td></td><td>_</td><td>-</td><td>_</td><td>-</td><td>_</td><td></td><td>-</td><td></td><td>-</td><td>-</td><td></td><td>7</td><td>_</td><td>-</td><td></td><td></td></t<>	_		-			_	-	_	-	_		-		-	-		7	_	-		
C69 Eye 2 0 0 0 0 2 0 1 1 1 0 0 0 0 0 2 0 1 1 1 0 <td></td> <td>•</td> <td></td> <td>12</td> <td></td> <td></td> <td></td> <td></td>		•															12				
C70-72 Brain 5 10 7 7 11 6 17 13 12 15 22 20 14 11 10 13 1 194 2.6 C73 Thyroid 0 1 0 3 6 8 10 15 10 8 6 3 13 9 4 8 0 104 1.4 C74-75 Other Endocrine Gland 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 0 0 1 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		•								-		-									
C73 Thyroid 0 1 0 3 6 8 10 15 10 8 6 3 13 9 4 8 0 104 1.4 C74-75 Other Endocrine Gland 1 1 0 0 1 1 0 0 1 2 0 0 0 1 1 1 0 10 0.1 C76 Other III Def Sites 1 0 0 0 1 0 1 1 0 0 1 1 2 0 0 0 1 1 1 0 2 0 13 0.2 C77 Lymph Nodes 0 0 0 0 1 1 0 1 1 2 0 0 4 2 2 0 2 1 16 0.2 C78 Sec Resp & Dig 0 0 0 0 1 2 0 1 0 2 1 3 2 7 7 0 26 0.3 C79 Sec Others 0 0 1 0 0 1 1 2 1 5 2 4 4 3 0 1 0 25 0.3 C80 Unknown Primary 1 1 3 1 3 1 0 3 6 7 10 10 8 9 12 17 1 93 1.2 C81 Hodgkin Lymphoma 0 1 0 2 3 1 2 2 3 3 1 2 2 1 5 2 0 30 0.4 C82-85 N.H.Lymphoma 1 3 2 3 2 8 8 8 13 8 20 22 15 17 24 20 1 175 2.3 C90 Multiple Myeloma 0 0 0 0 0 1 1 1 1 2 3 2 16 8 4 2 4 0 44 0.6 C91 Lymphoid Leukemia 3 7 7 5 3 3 2 2 2 4 2 1 0 1 3 3 0 48 0.6 C92 Myeloid Leukemia 3 2 0 0 0 0 1 3 3 2 4 2 4 0 2 2 0 28 0.4		•			-	-	-														
C74-75 Other Endocrine Gland 1 1 0 0 1 2 0 0 0 1 1 0 10 0.1 C76 Other III Def Sites 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 1 0 0 0 1 0 0 1 1 0 0 0 1 1 0 <td< td=""><td></td><td></td><td>_</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>			_																		
C76 Other III Def Sites 1 0 0 1 0 0 1 1 0 1 2 3 1 0 2 0 13 0.2 C77 Lymph Nodes 0 0 0 0 1 0 1 1 2 0 0 4 2 2 0 2 1 16 0.2 C78 Sec Resp & Dig 0 0 0 0 0 1 2 0 1 0 2 1 3 2 7 7 0 26 0.3 C79 Sec Others 0 0 1 0 0 1 1 2 1 5 2 4 4 3 0 1 0 25 0.3 C80 Unknown Primary 1 1 3 1 2 2 3 3 1 2 2 1 5 <td< td=""><td></td><td>•</td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>		•			-																
C77 Lymph Nodes 0 0 0 1 0 1 1 2 0 0 4 2 2 0 2 1 16 0.2 C78 Sec Resp & Dig 0 0 0 0 0 1 2 0 1 0 2 1 3 2 7 7 0 26 0.3 C79 Sec Others 0 0 1 0 0 1 1 2 1 5 2 4 4 3 0 1 0 25 0.3 C80 Unknown Primary 1 1 3 1 3 1 2 2 4 4 3 0 1 0 2 3 1 2 2 1 1 93 1.2 C81 Hodgkin Lymphoma 0 1 0 2 3 1 2 2 1 5<					-	-															
C78 Sec Resp & Dig 0 0 0 0 0 0 0 1 2 0 1 0 2 1 3 2 7 7 0 26 0.3 C79 Sec Others 0 0 1 0 0 1 1 2 1 5 2 4 4 3 0 1 0 25 0.3 C80 Unknown Primary 1 1 3 1 3 1 0 3 6 7 10 10 8 9 12 17 1 93 1.2 C81 Hodgkin Lymphoma 0 1 0 2 3 1 2 2 1 5 2 0 30 0.4 C82-85 N.H.Lymphoma 1 3 2 3 2 8 8 8 13 8 20 22 15 17 24					-	-															
C79 Sec Others 0 0 1 0 0 1 1 2 1 5 2 4 4 3 0 1 0 25 0.3 C80 Unknown Primary 1 1 3 1 3 1 0 3 6 7 10 10 8 9 12 17 1 93 1.2 C81 Hodgkin Lymphoma 0 1 0 2 3 1 2 2 1 5 2 0 30 0.4 C82-85 N.H.Lymphoma 1 3 2 3 2 8 8 8 13 8 20 22 15 17 24 20 1 175 2.3 C90 Multiple Myeloma 0 0 0 0 1 1 1 2 3 2 16 8 4 2 4 0 44		•																			
C80 Unknown Primary																					
C81 Hodgkin Lymphoma			0			0											-				
C82-85 N.H.Lymphoma	C80	•																			1.2
C90 Multiple Myeloma 0 0 0 0 1 1 1 2 3 2 16 8 4 2 4 0 44 0.6 C91 Lymphoid Leukemia 3 7 7 5 3 3 2 2 2 4 2 1 0 1 3 3 0 48 0.6 C92 Myeloid Leukemia 3 3 3 2 2 5 2 8 2 6 6 11 4 8 4 4 0 73 1.0 C93-95 Other Leukemia 3 2 0 0 0 0 1 3 3 2 4 2 4 0 2 2 0 28 0.4	C81	· , ,	0	1	0	2		1	2	2		3									0.4
C91 Lymphoid Leukemia 3 7 7 5 3 3 2 2 2 4 2 1 0 1 3 3 0 48 0.6 C92 Myeloid Leukemia 3 3 3 2 2 5 2 8 2 6 6 11 4 8 4 4 0 73 1.0 C93-95 Other Leukemia 3 2 0 0 0 0 1 3 3 2 4 2 4 0 2 2 0 28 0.4	C82-85	N.H.Lymphoma	1	3	2	3	2	8	8	8	13	8	20	22	15	17	24	20			2.3
C92 Myeloid Leukemia 3 3 3 2 2 5 2 8 2 6 6 11 4 8 4 4 0 73 1.0 C93-95 Other Leukemia 3 2 0 0 0 0 1 3 3 2 4 2 4 0 2 2 0 28 0.4	C90	Multiple Myeloma	0	0	0	0	0	1	1	1	2	3	2	16	8	4	2	4			0.6
C93-95 Other Leukemia 3 2 0 0 0 0 1 3 3 2 4 2 4 0 2 2 0 28 0.4	C91	Lymphoid Leukemia	3	7	7	5	3	3	2	2	2	4	2	1	0	1	3	3	0	48	0.6
C93-95 Other Leukemia 3 2 0 0 0 0 1 3 3 2 4 2 4 0 2 2 0 28 0.4	C92	•	3	3	3	2	2	5	2		2	6	6	11	4	8	4			73	1.0
		•					0	0					_		4		2	_			0.4
	Total	All Sites	28				81	154	220	414			892		933			848	_	-	100.0

Table 9: Average Annual Age-Specific, World Age Adjusted, Truncated (35-64) Incidence Rates of Cancer Cases per 100,000 Persons, Pune, 2006-10, Male

COOL	ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
CB3-06 Mourh	C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.2	0.8	1.4	2.3	0.7	1.2	0.2	0.3	0.5
C37-08 Sallsany Gland 00 01 00 00 00 00 00 00 00 00 00 00 00 0	C01-02	Tongue	0.0	0.0	0.0	0.0	0.1	0.7	2.5	3.6	4.5	4.4	5.9	12.1	12.3	11.0	15.0	15.0	2.5	3.2	6.5
C93+10 C95+10 C95	C03-06	Mouth	0.1	0.2	0.0	0.1	0.3	0.4	2.3	3.7	8.1	10.5	14.7	26.6	38.4	37.5	30.7	28.1	5.2	7.2	15.1
C11 Masophaynx	C07-08	Salivary Gland	0.0	0.1	0.0	0.0	0.0	0.1	0.4	0.2	0.5	0.3	0.7	1.1	1.1	3.7	0.0	2.5	0.3	0.4	0.6
C12-13 Hypopharymx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C09-10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.5	0.8	1.1	3.6	2.2	3.7	2.0	8.7	0.5	0.7	1.2
C141 Other Oral	C11	Nasopharynx	0.0	0.1	0.0	0.2	0.1	0.1	0.2	0.0	0.1	0.3	0.4	0.6	1.4	0.0	2.0	0.0	0.2	0.2	0.4
C15	C12-13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.5	0.5	3.8	4.8	6.5	5.9	9.2	15.0	0.9	1.4	2.3
C161 Stormach C17 Small Intestine C18 Oloo C18 Coloo C19 Coloo C10 Coloo	C14	Other Oral	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.9	0.3	1.8	1.4	0.7	1.9	0.2	0.3	0.5
C17 Small Intestine	C15	Oesophagus	0.0	0.0	0.0	0.0	0.1	0.1	0.5	1.1	1.7	2.9	6.8	12.6	19.2	28.8	28.8	62.5	3.1	4.7	6.3
C181 C1921 Return	C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.4	1.0	0.7	1.8	2.9	4.7	10.9	17.0	21.5	21.6	40.0	2.5	3.6	5.4
C19-21 Returm	C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.5	0.2	0.6	0.4	1.8	2.0	1.9	0.1	0.2	0.3
C22 Liver 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,	C18	Colon	0.0	0.0	0.0	0.3	0.1	0.4	0.4	0.9	2.0	2.7	3.8	8.4	11.9	15.5	21.6	32.5	2.0	3.0	4.3
C23-24 Gall Bladder	C19-21	Retum	0.0	0.0	0.0	0.1	0.3	0.9	0.9	1.2	2.1	2.6	7.2	9.5	14.1	22.8	17.7	24.4	2.4	3.3	5.3
C23-2	C22	Liver	0.1	0.0	0.0	0.0	0.1	0.1	0.3	0.7	1.1	2.6	4.7	8.4	15.9	20.6	25.5	43.1	2.3	3.5	4.8
C26 Oth Dig Org	C23-24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.5	0.5	0.2	0.9	3.4	3.6	6.4	7.8	5.6	0.6	0.9	
C30-31 Nose, Sinuse	C25	Pancreas	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.6	0.5	0.9	3.9	5.6	13.4	11.0	10.5	20.0	1.3	2.0	3.5
C30-31 Nose, Sinuse	C26	Oth Dig Org	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.7	1.2	0.0	0.1	0.0
C32 Larynx 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.3 0.7 0.0 0.0 0.0 0.7 0.2 0.3 0.7 0.7 0.9 0.8 0.8 0.1 0.1 0.1 0.2 0.3 0.7 0.5 0.3 0.8 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0	C30-31		0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.5	0.7	0.3	0.9	1.4	2.9	1.4	2.6	5.0	0.4	0.5	1.0
C33-34 Lung		Larynx	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.7	2.0	3.8	6.1	17.1	23.9	28.3	37.3	36.9	3.1	4.7	7.5
C40-41 Bone	C33-34	•	0.0	0.0	0.0	0.2	0.2	0.1	0.7	1.5	1.8	3.5	10.4	17.9	19.9	35.6	41.2	57.5	3.7	5.6	7.9
C40-41 Bone	C37-38	Mediastinum, Plura	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.9	0.3	1.1	0.5	0.0	1.9	0.1	0.2	0.4
C44 Skin Others	C40-41		0.0	0.1	0.4	0.8	0.3	0.7	0.4	0.2	0.5	0.9	0.5	2.0	1.8	1.4	1.3	1.2	0.5	0.6	0.9
C47 Nervous System 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.0 0.4 0.5 0.0 0.6 0.1 0.1 0.1 0.1 C48 Retroperitonium 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.6 0.4 0.0 0.7 0.0 0.1 0.1 0.1 0.2 C49 Conn & Soft Tissue 0.3 0.1 0.1 0.3 0.5 0.3 0.5 0.3 0.5 0.9 0.6 0.9 0.9 0.8 2.2 2.2 5.9 7.2 6.2 0.7 0.9 1.5 C60 Penis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.7 1.1 1.1 2.2 2.2 5.9 4.6 3.3 6.2 0.7 0.9 1.5 C60 Penis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.7 1.1 1.1 2.2 2.2 5.9 4.6 5.6 0.5 0.8 1.2 C61 Prostate 0.1 0.0 0.0 0.1 0.1 0.3 0.7 0.4 0.2 0.0 0.1 0.1 0.2 0.0 0.1 1.1 2.2 2.2 5.9 4.6 5.6 0.5 0.8 1.2 C61 Prostate 0.1 0.1 0.0 0.0 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	C43	Skin Melanoma	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.4	0.3	0.4	0.5	0.7	0.0	0.1	0.1	0.2
C47 Nervous System 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.0 0.4 0.5 0.0 0.6 0.1 0.1 0.1 0.1 C48 Retroperitonium 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.6 0.4 0.0 0.7 0.0 0.1 0.1 0.1 0.2 C49 Conn & Soft Tissue 0.3 0.1 0.1 0.3 0.5 0.3 0.5 0.3 0.5 0.9 0.6 0.9 0.9 0.8 2.2 2.2 2.9 5.9 7.2 6.2 0.7 0.9 1.5 C60 Penis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C44	Skin Others	0.0	0.0	0.1	0.1	0.5	0.1	0.0	0.4	0.4	0.3	1.6	1.7	5.1	5.0	4.6	10.0	0.7	0.9	1.3
C48 Retroperitionium 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.6 0.4 0.0 0.7 0.0 0.1 0.1 0.1 0.2 C49 Conn & Soft Tissue 0.3 0.1 0.1 0.1 0.3 0.5 0.3 0.5 0.9 0.6 0.9 0.9 0.8 2.2 2.4 6 3.3 6.2 0.7 0.9 1.2 C50 Breast 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1	C47		0.0				_	0.0	0.0	0.1	0.0				0.4						
C49 Conn & Soft Tissue 0.3 0.1 0.1 0.3 0.5 0.3 0.5 0.9 0.6 0.9 0.9 2.8 2.2 4.6 3.3 6.2 0.7 0.9 1.2 C50 Breast 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.3 0.7 1.5 2.0 2.2 2.9 5.9 7.2 6.2 0.7 0.9 1.5 C60 Penis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C48	•	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.0	0.2	0.6	0.4	0.0	0.7	0.0	0.1	0.1	0.2
C50 Breast 0.0<	C49	Conn & Soft Tissue	0.3	0.1	0.1	0.3	0.5	0.3	0.5	0.9	0.6	0.9	0.9	2.8	2.2	4.6	3.3	6.2	0.7	0.9	1.2
C60 Penis	C50	Breast	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.3	0.7	1.5	2.0	2.2	2.9	5.9	7.2	6.2	0.7	0.9	1.5
C62 Testis 0.0 0.0 0.1 0.1 0.1 0.3 0.7 0.4 0.2 0.0 0.5 0.2 0.0 0.4 0.0 0.7 1.9 0.2 0.2 0.2 0.6 0.3 Oth Male Gen Org 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.7	1.1	1.1	2.2	2.2	5.9	4.6	5.6	0.5	0.8	1.2
C63 Oth Male Gen Org	C61	Prostate	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	1.4	2.1	8.1	24.3	41.1	71.9	154.9	4.5	7.3	4.8
C64-65 Kidney 0.4 0.3 0.1 0.0 0.3 0.1 0.2 0.9 0.5 2.0 2.9 6.2 7.2 11.9 7.8 11.9 1.2 1.8 2.8 C66-68 Urinary Bladder 0.1 0.0 <td>C62</td> <td>Testis</td> <td>0.0</td> <td>0.0</td> <td>0.1</td> <td>0.1</td> <td>0.3</td> <td>0.7</td> <td>0.4</td> <td>0.2</td> <td>0.0</td> <td>0.5</td> <td>0.2</td> <td>0.0</td> <td>0.4</td> <td>0.0</td> <td>0.7</td> <td>1.9</td> <td>0.2</td> <td>0.2</td> <td>0.2</td>	C62	Testis	0.0	0.0	0.1	0.1	0.3	0.7	0.4	0.2	0.0	0.5	0.2	0.0	0.4	0.0	0.7	1.9	0.2	0.2	0.2
C66-68 Urinary Bladder 0.1 0.0 0.1 0.1 0.0 0.4 0.4 1.0 2.0 2.9 7.0 11.2 16.0 19.0 34.4 1.7 2.7 3.5 C69 Eye 0.2 0.0	C63	Oth Male Gen Org	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69 Eye 0.2 0.0 <td>C64-65</td> <td>Kidney</td> <td>0.4</td> <td>0.3</td> <td>0.1</td> <td>0.0</td> <td>0.3</td> <td>0.1</td> <td>0.2</td> <td>0.9</td> <td>0.5</td> <td>2.0</td> <td>2.9</td> <td>6.2</td> <td>7.2</td> <td>11.9</td> <td>7.8</td> <td>11.9</td> <td>1.2</td> <td>1.8</td> <td>2.8</td>	C64-65	Kidney	0.4	0.3	0.1	0.0	0.3	0.1	0.2	0.9	0.5	2.0	2.9	6.2	7.2	11.9	7.8	11.9	1.2	1.8	2.8
C70-72 Brain	C66-68	Urinary Bladder	0.1	0.0	0.0	0.1	0.1	0.0	0.4	0.4	1.0	2.0	2.9	7.0	11.2	16.0	19.0	34.4	1.7	2.7	3.5
C70-72 Brain	C69	Eye	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C74-75 Other Endocrine Gland	C70-72		0.6	2.1	0.5	1.0	0.9	1.8	2.4	3.3	2.3	5.5	4.1	9.8	7.2	10.5	11.1	6.2	2.5	3.0	5.0
C76 Other III Def Sites	C73	Thyroid	0.0	0.1	0.0	0.0	0.1	0.3	0.6	0.2	0.0	0.9	1.1	1.4	2.9	3.2	2.6	4.4	0.5	0.6	0.9
C77 Lymph Nodes	C74-75	Other Endocrine Gland	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	1.4	0.7	0.0	0.1	0.1	0.0
C77 Lymph Nodes 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.5 0.3 0.7 1.1 0.4 2.7 1.3 3.7 0.3 0.4 0.5 C78 Sec Resp & Dig 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C76																				
C78 Sec Resp & Dig																					
C79 Sec Others 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.2 0.4 0.6 1.4 1.4 1.3 0.6 0.2 0.2 0.4 C80 Unknown Primary 0.1 0.1 0.0 0.1 0.2 0.1 0.6 0.5 0.9 1.4 2.9 3.9 6.9 9.6 12.4 15.6 1.2 1.7 2.4 C81 Hodgkin Lymphoma 0.4 0.3 0.2 0.5 0.1 0.1 0.3 0.6 0.4 0.2 1.1 0.6 2.2 0.9 2.6 1.2 0.4 0.5 0.8 C82-85 N.H.Lymphoma 0.2 0.6 0.9 0.7 0.3 0.4 1.5 2.9 2.8 3.0 4.8 8.1 10.5 18.3 23.5 30.0 2.6 3.5 4.9 C90 Multiple Myeloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C78							_					0.2		2.5	3.2					
C80 Unknown Primary 0.1 0.1 0.0 0.1 0.2 0.1 0.6 0.5 0.9 1.4 2.9 3.9 6.9 9.6 12.4 15.6 1.2 1.7 2.4 C81 Hodgkin Lymphoma 0.4 0.3 0.2 0.5 0.1 0.1 0.3 0.6 0.4 0.2 1.1 0.6 2.2 0.9 2.6 1.2 0.4 0.5 0.8 C82-85 N.H.Lymphoma 0.2 0.6 0.9 0.7 0.3 0.4 1.5 2.9 2.8 3.0 4.8 8.1 10.5 18.3 23.5 30.0 2.6 3.5 4.9 C90 Multiple Myeloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.3 1.4 2.2 4.3 6.4 8.5 5.0 0.6 0.9 1.3 C91 Lymphoid Leukemia 0.6 2.4 0.6 0.2 0.5 0.5 0.4 0.1 0.5 0.8 0.5 0.6 0.7 1.8 0.7 1.9 0.7 0.8 0.5 C92 Myeloid Leukemia 0.4 0.3 0.5 0.4 0.1 0.6 0.5 0.7 0.4 0.8 1.1 1.7 3.6 4.1 5.2 7.5 0.8 1.0 1.2 C93-95 Other Leukemia 0.0 0.2 0.1 0.2 0.0 0.1 0.1 0.4 0.4 0.2 0.4 0.6 2.2 0.9 3.3 1.2 0.3 0.4 0.6	C79		0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.2	0.2	0.4	0.6	1.4	1.4	1.3	0.6	0.2	0.2	0.4
C81 Hodgkin Lymphoma	C80	Unknown Primary	0.1	0.1	0.0	0.1	0.2	0.1	0.6	0.5	0.9	1.4	2.9	3.9	6.9	9.6	12.4	15.6	1.2		2.4
C82-85 N.H.Lymphoma	C81	-	0.4	0.3	0.2	0.5	0.1														
C90 Multiple Myeloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	C82-85	N.H.Lymphoma	0.2	0.6	0.9	0.7	0.3	_			2.8				10.5						
C91 Lymphoid Leukemia 0.6 2.4 0.6 0.2 0.5 0.4 0.1 0.5 0.8 0.5 0.6 0.7 1.8 0.7 1.9 0.7 0.8 0.5 C92 Myeloid Leukemia 0.4 0.3 0.5 0.4 0.1 0.6 0.5 0.7 0.4 0.8 1.1 1.7 3.6 4.1 5.2 7.5 0.8 1.0 1.2 C93-95 Other Leukemia 0.0 0.2 0.1 0.2 0.0 0.1 0.1 0.4 0.2 0.4 0.6 2.2 0.9 3.3 1.2 0.3 0.4 0.6																					
C92 Myeloid Leukemia 0.4 0.3 0.5 0.4 0.1 0.6 0.5 0.7 0.4 0.8 1.1 1.7 3.6 4.1 5.2 7.5 0.8 1.0 1.2 C93-95 Other Leukemia 0.0 0.2 0.1 0.2 0.0 0.1 0.1 0.4 0.4 0.2 0.4 0.6 2.2 0.9 3.3 1.2 0.3 0.4 0.6																					
C93-95 Other Leukemia 0.0 0.2 0.1 0.2 0.0 0.1 0.1 0.4 0.4 0.2 0.4 0.6 2.2 0.9 3.3 1.2 0.3 0.4 0.6								_													
		-						_													
													111.9					722.0			

Table 10: Average Annual Age-Specific, World Age Adjusted, Truncated (35-64) Incidence Rates of Cancer Cases per 100,000 Persons, Pune, 2006-10, Female

	Persons, Pune, 2006-1	lu, f																_		
ICD-10		0	5	_		20	25	30	35	40	45	50		60	65	70				TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.6	1.0	1.9	1.8	0.0	0.1	0.2	0.3
C01-02	Tongue	0.0	0.0	0.0	0.0	0.1	0.1	0.9	0.8	2.2	2.5	3.7	6.8	6.9	3.8	6.0	3.5	1.2	1.4	3.4
C03-06	Mouth	0.0	0.0	0.0	0.0	0.2	0.3	0.4	1.5	3.0	5.1	10.0	12.4	21.8	18.6	15.5	21.9	3.0	3.8	7.9
C07-08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.2	0.3	0.5	0.2	0.6	0.0	0.8	1.8	1.2	0.2	0.2	0.3
C09-10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.0	0.9	1.0	0.0	0.6	0.6	0.1	0.2	0.4
C11	Nasopharynx	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.1	0.3	0.0	0.2	0.3	0.0	0.0	0.6	0.6	0.1	0.1	0.2
C12-13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	1.1	1.4	1.5	1.2	2.4	1.5	1.8	0.0	0.4	0.5	1.2
C14	Other Oral	0.0	0.0		0.0	_	0.0	0.0	0.0	0.0	0.3	0.4	0.6	1.0	0.0	0.0	2.3	0.1	0.2	0.3
C15	Oesophagus	0.0	0.0		0.0	_	0.1	0.3	0.9	1.9	4.3	4.8	8.3	13.9	16.0	20.9	35.8	2.4	3.2	5.0
C16	Stomach				_	0.0	0.3	0.5	0.9	0.4	1.3	3.3	5.3	6.2	7.6	8.3	12.7	1.2	1.5	2.5
C17	Small Intestine				0.0		0.0	0.0	0.0	0.1	0.2	0.0	0.3	0.7	0.0	1.8	1.7	0.1	0.1	0.2
C18	Colon				0.1	_	0.6	0.1	0.5	1.4	1.4	2.6	6.2	6.6	7.2	18.5	23.7	1.6	2.0	2.7
C19-21	Retum				0.0		0.4	0.5	1.3	1.6	1.7	4.1	8.7	11.1	9.9	14.3	12.7	1.7	2.2	4.1
C22	Liver			_	0.0	_	0.2	0.3	0.5	1.0	0.5	2.2	4.0	4.2	6.5	6.6	18.5	1.0	1.3	1.8
	-	-	-		0.0	_		0.3	0.3	0.7	1.1	2.4	3.4	4.5	3.4		13.8		1.1	1.8
C25-24	Gall Bladder			_	_	_	0.1									4.8			1.1	1.0
	Pancreas				0.0		0.1	0.4	0.3	0.4	1.3	2.4	2.8	4.5	7.2	7.7	14.4	1.0		
C26	Oth Dig Org				0.0	_	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0		0.0	0.0
C30-31	Nose, Sinuse	_			0.0	_	0.0	0.1	0.0	0.9	0.3	0.2	0.9	1.7	1.1	2.4	4.0		0.4	0.6
C32	Larynx				0.0	_	0.0	0.3	0.3	0.7	0.5	1.1	0.9	2.8	3.4	5.4	9.8		0.7	0.9
	Lung				0.0	_	0.2	0.3	1.3	2.6	3.2	6.3	11.1	11.1	12.9	16.7	23.1	2.2	2.8	5.3
C37-38	Mediastinum, Plura	0.1			0.0		0.1	0.1	0.0	0.1	0.0	0.2	0.3	0.7	1.1	1.2	1.2	0.1	0.2	0.2
C40-41	Bone	0.1			0.5		0.5	0.0	0.4	0.0	0.5	0.9	1.5	0.3	0.8	1.2	0.0	0.5	0.5	0.6
C43	Skin Melanoma	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.6	1.2	0.1	0.1	0.1
C44	Skin Others	0.0	0.0	0.1	0.0	0.0	0.2	0.3	0.3	0.6	1.0	0.9	2.2	2.4	2.7	6.6	7.5	0.6	0.7	1.1
C47	Nervous System	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
C48	Retroperitonium	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.4	0.2	0.0	0.3	0.0	0.8	1.8	0.0	0.1	0.1	0.2
C49	Conn & Soft Tissue	0.1	0.1	0.2	0.1	0.2	0.5	0.2	0.4	0.9	0.8	2.0	1.9	2.1	2.3	3.0	4.0	0.6	0.7	1.2
C50	Breast	0.0	0.1	0.1	0.0	0.6	3.0	7.4	14.2	33.1	47.9	64.7	90.6	91.5	82.6	84.6	120.6	19.2	23.6	52.4
C51-52	Oth Fem Gen Org	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.5	0.7	0.6	1.7	2.5	3.8	1.5	4.2	1.7	0.5	0.6	1.5
C53	Cervix	0.0	0.0	0.0	0.0	0.2	1.3	2.3	8.6	15.5	21.6	35.0	43.9	50.6	43.4	40.5	34.6	9.2	11.3	26.7
C54	Corpus Uteri	0.0	0.0	0.0	0.0	0.1	0.2	0.2	1.0	0.7	3.2	9.8	12.4	15.3	16.0	12.5	15.6	2.3	3.0	6.1
C55	Uterus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.8	0.9	0.3	2.1	1.1	4.8	4.0	0.3	0.4	0.7
C56	Ovary	0.2	0.1	0.3	0.5	0.4	0.9	1.5	2.9	4.9	9.7	11.5	18.9	18.7	21.7	21.4	34.0		5.2	10.1
	Oth Unsp Fem Gen Org		0.0			0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.4	0.0	0.0		0.0	0.1
C64-65	-	-			0.0	_	0.2	0.0	0.3	1.1	0.8	2.0	2.5	3.1	3.4	4.2	3.5		0.8	1.5
	Urinary Bladder	_			0.1	_	0.0	0.1	0.1	0.3	0.2	1.3		2.4	3.8	7.7	11.5			
C69	Eye				0.0		0.0	0.2	0.0	0.1	0.2	0.2		0.3	0.0	0.0	0.0		0.1	0.1
C70-72	-				0.6		0.5	1.7	1.4		2.4	4.8		4.9	4.2	6.0	7.5		1.9	3.3
C73	Thyroid				0.3		0.7	1.0	1.6	1.4	1.3	1.3		4.5	3.4	2.4	4.6			1.8
	Other Endocrine Gland				0.0		0.1	0.0	0.0	0.1	0.3	0.0		0.0	0.4	0.6	0.6		0.1	0.1
C76	Other III Def Sites				0.0		0.0	0.0	0.1	0.1	0.0	0.2		1.0	0.4	0.0	1.2		0.1	0.3
					0.0		0.0	0.0	0.1	_	0.0				0.4		1.2		0.1	0.3
	Lymph Nodes				0.0		0.0	0.1	0.1	0.3		0.0		0.7	0.8	0.0 4.2	4.0		0.2	
	Sec Resp & Dig									0.1	0.0	0.4		1.0						
C79	Sec Others				0.0		0.1	0.1	0.2	0.1	0.8	0.4		1.4	1.1	0.0	0.6		0.3	0.6
C80	Unknown Primary				0.1		0.1	0.0	0.3	0.9	1.1	2.2		2.8	3.4	7.1	9.8			1.6
C81	Hodgkin Lymphoma				0.2		0.1	0.2	0.2	0.4	0.5	0.2		0.7	0.4	3.0	1.2			0.4
	N.H.Lymphoma				0.3		0.7	8.0	0.9	1.9	1.3	4.3		5.2	6.5	14.3	11.5			3.0
	Multiple Myeloma				0.0		0.1	0.1	0.1	0.3	0.5	0.4		2.8	1.5	1.2	2.3		0.5	1.2
	Lymphoid Leukemia				0.5		0.2	0.2	0.2	0.3	0.6	0.4		0.0	0.4	1.8	1.7	0.4	0.4	0.3
	Myeloid Leukemia				0.2	_	0.4	0.2	0.9	0.3	1.0	1.3		1.4	3.0	2.4	2.3			1.2
	Other Leukemia				0.0		0.0	0.1	0.3		0.3	0.9		1.4	0.0	1.2	1.2			
Total	All Sites	3.0	4.1	3.7	3.7	6.5	12.6	21.9	45.0	86.2	123.9	193.8	286.0	323.5	309.7	373.5	489.3	64.8	80.2	159.3

Table 11: Incidence Cases of Cancer by Most Valid Basis of Diagnosis and Site (ICD10) with Percentage, Pune, 2006-10, Male

ICD-10	SITE	Micro	scopic	Clin I	nvst		nical	DC	O	To	tal
		#	%	#	%	#	%	#	%	#	%
C00	Lip	19	0.3	0	0.0	1	0.2	1	0.2	21	0.3
C01-02	Tongue	291	4.9	2	2.2	22	5.3	9	2.1	324	4.7
C03-06	Mouth	582	9.9	2	2.2	68	16.4	19	4.5	671	9.8
C07-08	Salivary Gland	25	0.4	1	1.1	11	2.7	1	0.2	38	0.6
C09-10	Oropharynx	55	0.9	0	0.0	6	1.4	2	0.5	63	0.9
C11	Nasopharynx	21	0.4	1	1.1	2	0.5	0	0.0	24	0.4
C12-13	Hypopharynx	109	1.8	1	1.1	6	1.4	5	1.2	121	1.8
C14	Other Oral	15	0.3	0	0.0	3	0.7	7	1.7	25	0.4
C15	Oesophagus	303	5.1	8	8.8	29	7.0	56	13.4	396	5.8
C16	Stomach	258	4.4	4	4.4	17	4.1	37	8.8	316	4.6
C17	Small Intestine	15	0.3	0	0.0	3	0.7	1	0.2	19	0.3
C18	Colon	230	3.9	2	2.2	12	2.9	18	4.3	262	3.8
C19-21	Retum	260	4.4	4	4.4	20	4.8	19	4.5	303	4.4
C22	Liver	272	4.6	2	2.2	6	1.4	14	3.3	294	4.3
C23-24	Gall Bladder	59	1.0	2	2.2	9	2.2	6	1.4	76	1.1
C25	Pancreas	109	1.8	2	2.2	28	6.7	33	7.9	172	2.5
C26	Oth Dig Org	1	0.0	0	0.0	0	0.0	3	0.7	4	0.1
C30-31	Nose, Sinuse	44	0.7	1	1.1	3	0.7	2	0.5	50	0.7
C32	Larynx	336	5.7	3	3.3	39	9.4	17	4.1	395	5.8
C33-34	Lung	377	6.4	11	12.1	37	8.9	54	12.9	479	7.0
C37-38	Mediastinum, Plura	14	0.2	0	0.0	1	0.2	1	0.2	16	0.2
C40-41	Bone	65	1.1	0	0.0	2	0.5	2	0.5	69	1.0
C43	Skin Melanoma	10	0.2	0	0.0	0	0.0	0	0.0	10	0.1
C44	Skin Others	82	1.4	1	1.1	0	0.0	1	0.2	84	1.2
C47	Nervous System	7	0.1	0	0.0	1	0.2	0	0.0	8	0.1
C48	Retroperitonium	10	0.2	0	0.0	0	0.0	0	0.0	10	0.1
C49	Conn & Soft Tissue	91	1.5	0	0.0	0	0.0	0	0.0	91	1.3
C50	Breast	71	1.2	3	3.3	5	1.2	8	1.9	87	1.3
C60	Penis	62	1.0	0	0.0	5	1.2	1	0.2	68	1.0
C61	Prostate	481	8.1	4	4.4	32	7.7	56	13.4	573	8.4
C62	Testis	29	0.5	0	0.0	0	0.0	3	0.7	32	0.5
C63	Oth Male Gen Org	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
C64-65	Kidney	148	2.5	1	1.1	3	0.7	4	1.0	156	2.3
	•	204	3.5	1	1.1	6	1.4	14	3.3	225	3.3
C69	Eye	4	0.1	0	0.0	0	0.0	0	0.0		0.1
C70-72	Brain	293	5.0	27	29.7	6	1.4	1	0.2	327	4.8
C73	Thyroid	56	0.9	1	1.1	1	0.2	0	0.0	58	0.8
C74-75	Other Endocrine Gland	9	0.2	0	0.0	0	0.0	0	0.0	9	0.1
C76	Other III Def Sites	18	0.3	0	0.0	3	0.7	5	1.2	26	0.4
C77	Lymph Nodes	35	0.6	0	0.0	0	0.0	0	0.0	35	0.5
C78	Sec Resp & Dig	34	0.6	0	0.0	1	0.2	0	0.0	35	0.5
C79	Sec Others	20	0.3	0	0.0	0	0.0	0	0.0	20	0.3
C80	Unknown Primary	96	1.6	7	7.7	27	6.5	19	4.5	149	2.2
C81	Hodgkin Lymphoma	54	0.9	0	0.0	0	0.0	0	0.0	54	0.8
C82-85		335	5.7	0	0.0	0	0.0	0	0.0		4.9
C90	Multiple Myeloma	74	1.3	0	0.0	0	0.0	0	0.0	74	1.1
	Lymphoid Leukemia	87		0				0		87	1.1
C91			1.5		0.0	0	0.0		0.0		
C92	Myeloid Leukemia	100	1.7	0	0.0	0	0.0	0	0.0		1.5
C93-95	Other Leukemia	35	0.6	0	0.0	0	0.0	0	0.0	35	0.5
Total	All Sites	5906	100.0	91	100.0	415	100.0	419	100.0	6831	100.0

Table12: Incidence Cases of Cancer by Most Valid Basis of Diagnosis and Site (ICD10) with Percentage, Pune, 2006-10, Female

C01-02 Tongue 125 1.9 0 0.0 7 1.9 3 C03-06 Mouth 299 4.5 1 1.7 26 7.0 16 C07-08 Salivary Gland 19 0.3 0 0.0 2 0.5 0 C09-10 Oropharynx 13 0.2 0 0.0 1 0.3 0 C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	b # 0.0 17 13.5 342 0.0 2° 0.0 14 0.2 1° 0.0 46 0.9 13	5 1.8 2 4.6 1 0.3 4 0.2 1 0.1
C00 Lip 16 0.2 0 0.0 1 0.3 0 C01-02 Tongue 125 1.9 0 0.0 7 1.9 3 C03-06 Mouth 299 4.5 1 1.7 26 7.0 16 C07-08 Salivary Gland 19 0.3 0 0.0 2 0.5 0 C09-10 Oropharynx 13 0.2 0 0.0 1 0.3 0 C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10	0.0 17 0.7 135 3.5 342 0.0 2° 0.0 14 0.2 1° 0.0 46 0.9 13	7 0.2 5 1.8 2 4.6 1 0.3 4 0.2 1 0.1
C01-02 Tongue 125 1.9 0 0.0 7 1.9 3 C03-06 Mouth 299 4.5 1 1.7 26 7.0 16 C07-08 Salivary Gland 19 0.3 0 0.0 2 0.5 0 C09-10 Oropharynx 13 0.2 0 0.0 1 0.3 0 C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	0.7 138 3.5 342 0.0 2° 0.0 14 0.2 1° 0.0 46 0.9 13	5 1.8 2 4.6 1 0.3 4 0.2 1 0.1
C03-06 Mouth 299 4.5 1 1.7 26 7.0 16 C07-08 Salivary Gland 19 0.3 0 0.0 2 0.5 0 C09-10 Oropharynx 13 0.2 0 0.0 1 0.3 0 C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	3.5 342 0.0 2 ² 0.0 14 0.2 1 ² 0.0 46 0.9 13	2 4.6 1 0.3 4 0.2 1 0.1
C07-08 Salivary Gland 19 0.3 0 0.0 2 0.5 0 C09-10 Oropharynx 13 0.2 0 0.0 1 0.3 0 C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	0.0 2° 0.0 14 0.2 1° 0.0 46 0.9 1°	1 0.3 4 0.2 1 0.1
C09-10 Oropharynx 13 0.2 0 0.0 1 0.3 0 C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	0.0 14 0.2 17 0.0 46 0.9 13	4 0.2 1 0.1
C11 Nasopharynx 8 0.1 1 1.7 1 0.3 1 C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	0.2 1° 0.0 46 0.9 1°	0.1
C12-13 Hypopharynx 43 0.7 0 0.0 3 0.8 0 C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14	0.0 46 0.9 13	
C14 Other Oral 7 0.1 0 0.0 2 0.5 4 C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14).9 13	_
C15 Oesophagus 213 3.2 5 8.6 23 6.2 40 C16 Stomach 108 1.6 3 5.2 10 2.7 14		0.6
C16 Stomach 108 1.6 3 5.2 10 2.7 14		3 0.2
	3.7 28°	1 3.8
C17 Small Intestine 8 0.1 0 0.0 2 0.5 1	3.0 13	5 1.8
).2 1 ⁻	1 0.1
C18 Colon 152 2.3 1 1.7 8 2.2 20	1.3 18°	1 2.4
C19-21 Return 175 2.7 2 3.4 9 2.4 11	2.4 197	7 2.6
	2.6 12°	
	2.6 9	5 1.3
	3.5 110	
		1 0.0
	0.2 33	
	2.4 6	
	3.7 256	
	0.0 15	
).4 54	
		8 0.1
	0.2 69	
		2 0.0
	0.2 12	
·	0.2 12	
	3.9 222	
	0.9 222	
	5.9 1062	
	3.7	
	3.0 486	
		3 0.0
).4 74	
•	0.9 73	
·		8 0.1
	0.7 194	
	0.7 104	
).0 10	
).4 13	
•	0.0	
·	0.0	
C79 Sec Others 25 0.4 0 0.0 0 0.0 0	0.0	5 0.3
•	2.6 93	3 1.2
C81 Hodgkin Lymphoma 30 0.5 0 0.0 0 0.0 0).0	0.4
C82-85 N.H.Lymphoma 175 2.7 0 0.0 0 0.0 0	0.0 175	5 2.3
•	0.0 44	
·	0.0 48	3 0.6
	0.0 73	
	0.0 28	
	0.0 747	

Table 13: Incidence Cases of Cancer by Religion and Site (ICD10) with Crude Incidence Rate (CR), Pune, 2006-10, Male

ICD-10	SITE	Hin	du	Mus	lim	Chris	tian	Othe	ers	Tot	tal
		CR	%	CR	%	CR	%	CR	%	CR	%
C00	Lip	21	0.2	0	0.0	0	0.0	0	0.0	21	0.2
C01-02	Tongue	279	2.7	31	2.7	5	1.5	9	0.8	324	2.5
C03-06	Mouth	585	5.7	63	5.5	6	1.8	17	1.5	671	5.2
C07-08	Salivary Gland	30	0.3	5	0.4	0	0.0	3	0.3	38	0.3
C09-10	Oropharynx	49	0.5	8	0.7	4	1.2	2	0.2	63	0.5
C11	Nasopharynx	19	0.2	3	0.3	1	0.3	1	0.1	24	0.2
C12-13	Hypopharynx	102	1.0	14	1.2	2	0.6	3	0.3	121	0.9
C14	Other Oral	20	0.2	4	0.3	1	0.3	0	0.0	25	0.2
C15	Oesophagus	349	3.4	25	2.2	14	4.1	8	0.7	396	3.1
C16	Stomach	269	2.6	32	2.8	8	2.4	7	0.6	316	2.5
C17	Small Intestine	16	0.2	1	0.1	0	0.0	2	0.2	19	0.1
C18	Colon	241	2.4	13	1.1	3	0.9	5	0.4	262	2.0
C19-21	Retum	259	2.5	28	2.4	7	2.1	9	0.8	303	2.4
C22	Liver	262	2.6	19	1.7	7	2.1	6	0.5	294	2.3
C23-24	Gall Bladder	70	0.7	4	0.3	2	0.6	0	0.0	76	0.6
C25	Pancreas	143	1.4	22	1.9	5	1.5	2	0.2	172	1.3
C26	Oth Dig Org	3	0.0	1	0.1	0	0.0	0	0.0	4	0.0
C30-31	Nose, Sinuse	43	0.4	5	0.4	2	0.6	0	0.0	50	0.4
C32	Larynx	349	3.4	30	2.6	10	2.9	6	0.5	395	3.1
C33-34		400	3.9	47	4.1	20	5.9	12	1.1	479	3.7
	Mediastinum, Plura	14	0.1	1	0.1	1	0.3	0	0.0	16	0.1
C40-41	Bone	63	0.6	3	0.3	2	0.6	1	0.1	69	0.5
C43	Skin Melanoma	8	0.1	1	0.1	1	0.3	0	0.0	10	0.1
C44	Skin Others	69	0.7	10	0.1	2	0.6	3	0.3	84	0.7
C47	Nervous System	6	0.1	2	0.2	0	0.0	0	0.0	8	0.1
C48	Retroperitonium	8	0.1	1	0.2	0	0.0	1	0.1	10	0.1
C49	Conn & Soft Tissue	80	0.1	10	0.9	1	0.3	0	0.0	91	0.7
C50	Breast	60	0.6	15	1.3	10	2.9	2	0.2	87	0.7
C60	Penis	66	0.6	1	0.1	1	0.3	0	0.0	68	0.7
C61	Prostate	490	4.8	47	4.1	21	6.2	15	1.3	573	4.5
C62	Testis	28	0.3	2	0.2	2	0.2	0	0.0	32	0.2
C63	Oth Male Gen Org	1	0.0	0	0.2	0	0.0	0	0.0	1	0.2
C64-65	Kidney	132	1.3	17	1.5	5	1.5	2	0.0	156	1.2
C66-68	Urinary Bladder	183	1.8	32	2.8	10	2.9	0	0.2	225	1.7
C69	•	3	0.0	0	0.0		0.0	1	0.0	4	0.0
C70-72	Eye Brain	293	2.9	20	1.7	7	2.1	7	0.1	327	2.5
C70-72	Thyroid	43	0.4	12	1.7	3	0.9	0	0.0	58	0.5
C74-75	Other Endocrine Gland		0.4		0.0		0.9		0.0		
C74-75	Other III Def Sites	8 21	0.1	0	0.0	0	0.0	1	0.1	9 26	0.1 0.2
C76	Lymph Nodes	28	0.2	4	0.3	3	0.3	0	0.0	35	0.2
C78	Sec Resp & Dig	31	0.3	2	0.3	2	0.9	0	0.0	35	0.3
C78	Sec Others	16	0.3	2	0.2		0.6				
						1		1	0.1	20	0.2
C80	Unknown Primary	122	1.2	21	1.8	2	0.6	4	0.4	149	1.2
C81	Hodgkin Lymphoma	47	0.5	4	0.3	1	0.3	2	0.2	54	0.4
C82-85	N.H.Lymphoma	296	2.9	25	2.2	9	2.7	5	0.4	335	2.6
C90	Multiple Myeloma	63	0.6	7	0.6	4	1.2	0	0.0	74	0.6
C91	Lymphoid Leukemia	69	0.7	13	1.1	4	1.2	1	0.1	87	0.7
C92	Myeloid Leukemia	88	0.9	8	0.7	1	0.3	3	0.3	100	0.8
C93-95	Other Leukemia	28	0.3	4	0.3	2	0.6	1	0.1	35	0.3
Total	All Sites	5873	57.3	623	54.5	193	56.8	142	12.6	6831	53.1

Table 14: Incidence Cases of Cancer by Religion and Site (ICD10) with Crude Incidence Rate (CR), Pune, 2006-10, Female

ICD-10	SITE	Hin		Mus		Chris		Othe		Tot	
102 10	0.1.2	CR	%	CR	%	CR	%	CR	%	CR	%
C00	Lip	17	0.2	0	0.0	0	0.0	0	0.0	17	0.1
C01-02		120	1.3	12	1.2	0	0.0	3	0.3	135	1.2
C03-06		302	3.3	21	2.0	4	1.4	15	1.5	342	3.0
C07-08	Salivary Gland	16	0.2	4	0.4	0	0.0	1	0.1	21	0.2
	Oropharynx	12	0.1	0	0.0	0	0.0	2	0.2	14	0.1
	Nasopharynx	9	0.1	1	0.1	0	0.0	1	0.1	11	0.1
	Hypopharynx	43	0.5	3	0.3	0	0.0	0	0.0	46	0.4
C14	Other Oral	10	0.1	2	0.2	0	0.0	1	0.1	13	0.1
C15	Oesophagus	260	2.8	11	1.1	4	1.4	6	0.6	281	2.4
C16	Stomach	121	1.3	7	0.7	3	1.0	4	0.4	135	1.2
C17	Small Intestine	10	0.1	0	0.0	0	0.0	1	0.1	11	0.1
C18	Colon	159	1.7	14	1.4	2	0.7	6	0.6	181	1.6
	Retum	172	1.9	16	1.6	1	0.3	8	0.8	197	1.7
C22	Liver	106	1.1	9	0.9	3	1.0	3	0.3	121	1.0
C23-24	Gall Bladder	84	0.9	6	0.6	0	0.0	5	0.5	95	0.8
	Pancreas	100	1.1	8	0.8	0	0.0	2	0.2	110	1.0
C26	Oth Dig Org	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	Nose, Sinuse	30	0.3	2	0.2	1	0.3	0	0.0	33	0.3
C32	Larynx	55	0.6	8	0.8	1	0.3	1	0.1	65	0.6
	Lung	225	2.4	23	2.2	3	1.0	5	0.5	256	2.2
	Mediastinum, Plura	13	0.1	2	0.2	0	0.0	0	0.0	15	0.1
	Bone	50	0.5	3	0.3	0	0.0	1	0.1	54	0.5
C43	Skin Melanoma	6	0.1	2	0.2	0	0.0	0	0.0	8	0.1
C44	Skin Others	59	0.6	4	0.4	4	1.4	2	0.2	69	0.6
	Nervous System	2	0.0	0	0.0	0	0.0	0	0.0	2	0.0
C48	Retroperitonium	10	0.1	1	0.1	1	0.3	0	0.0	12	0.1
C49	Conn & Soft Tissue	60	0.7	7	0.7	2	0.7	2	0.2	71	0.6
	Breast	1937	21.0	168	16.4	55	19.0	61	6.1	2221	19.2
	Oth Fem Gen Org	50	0.5	5	0.5	1	0.3	1	0.1	57	0.5
C53	Cervix	957	10.4	62	6.0	16	5.5	27	2.7	1062	9.2
C54	Corpus Uteri	215	2.3	27	2.6	11	3.8	7	0.7	260	2.3
C55	Uterus	35	0.4	1	0.1	2	0.7	0	0.0	38	0.3
C56	Ovary	438	4.7	34	3.3	10	3.4	4	0.4	486	4.2
	Oth Unsp Fem Gen Org	2	0.0	0	0.0	10	0.3	0	0.0	3	0.0
C64-65		66	0.7	5	0.5	2	0.7	1	0.1	74	0.6
	Urinary Bladder	66	0.7	3	0.3	3	1.0	1	0.1	73	0.6
	Eye	7	0.1	1	0.1	0	0.0	0	0.0	8	0.1
	Brain	180	2.0	5	0.5	5	1.7	4	0.4	194	1.7
C73	Thyroid	85	0.9	14	1.4	3	1.0	2	0.2	104	0.9
C74-75	Other Endocrine Gland	8	0.1	1	0.1	0	0.0	1	0.1	104	0.1
C76	Other III Def Sites	13	0.1	0	0.0	0	0.0	0	0.0	13	0.1
C77	Lymph Nodes	15	0.1	0	0.0	0	0.0	1	0.1	16	0.1
C78	Sec Resp & Dig	23	0.2	2	0.2	1	0.3	0	0.0	26	0.2
C79	Sec Others	22	0.2	2	0.2	1	0.3	0	0.0	25	0.2
C80	Unknown Primary	83	0.2	6	0.6	3	1.0	1	0.0	93	0.8
C81	Hodgkin Lymphoma	26	0.9	3	0.8	0	0.0	1	0.1	30	0.8
	N.H.Lymphoma	154	1.7	14	1.4	3	1.0	4	0.1	175	1.5
	Multiple Myeloma	37	0.4	3	0.3	2	0.7	2	0.4	44	0.4
C90	Lymphoid Leukemia	39	0.4	7	0.3	1	0.7	1	0.2	48	0.4
	Myeloid Leukemia	66	0.4	4	0.7	1	0.3	2	0.1	73	0.4
	-		0.7	1						28	
	Other Leukemia	26			0.1	150	0.0	101	0.1		0.2
Total	All Sites	6602	71.5	534	52.1	150	51.7	191	19.2	7477	64.8

Table 15: Number of Incidence Cases of Cancer by Histology (ICDO3) and Sex, Pune, 2006-10

ICD-O-3	HISTOLOGY	Ма		Fem	ale	То	
		#	%	#	%	#	%
800	Malignant Neoplasms, Nos	919	13.5	883	11.8	1802	12.6
8001-8005	Malignant Tumors	140	2.0	156	2.1	296	2.1
801-804	Malignant Epithelial Neoplasm	251	3.7	179	2.4	430	3.0
805-808	Squamus Cell Neoplasms	1978	29.0	1881	25.2	3859	27.0
809-811	Basal Cell Neoplasms	26	0.4	28	0.4	54	0.4
812-813	Transitional Cell Carcinoma	189	2.8	63	0.8	252	1.8
814-838	Adenocarcinomas	1928	28.2	1356	18.1	3284	23.0
839-842	Skin Appendage Neoplasms	1	0.0	0	0.0	1	0.0
843	Mucoepidermoid Neoplasm	10	0.1	3	0.0	13	0.1
844-849	Cystic, Mucious & Serous Neoplasm	98	1.4	244	3.3	342	2.4
850-854	Ductal and Lobular Neoplasm	71	1.0	1924	25.7	1995	13.9
855	Acinar Cell Neoplasms	2	0.0	0	0.0	2	0.0
856-857	Complex Epithelial Neoplasms	0	0.0	7	0.1	7	0.0
858	Thymic Epithelial Neoplasms	2	0.0	1	0.0	3	0.0
859-867	Specialised Gonadal Neoplasm	0	0.0	1	0.0	1	0.0
872-879	Nevi and Melanomas	17	0.2	12	0.2	29	0.2
880	Soft Tissue Tumors and Sarcomas	61	0.9	46	0.6	107	0.7
881-883	Fibromatous Neoplasms	7	0.1	11	0.1	18	0.1
885-888	Lipomatous Neoplasms	7	0.1	2	0.0	9	0.1
889-892	Myomatous Neoplasms	21	0.3	19	0.3	40	0.3
893-899	Complex mixed and stromal Neoplasm	15	0.2	15	0.2	30	0.2
900-903	Fibroepithelial Neoplasms	0	0.0	8	0.1	8	0.1
904	Synovial Neoplasms	6	0.1	3	0.0	9	0.1
905	Mesothelial Neoplasms	3	0.0	1	0.0	4	0.0
906-909	Germ Cell Neoplasms	28	0.4	13	0.2	41	0.3
910	Triphoblastic Neoplasms	0	0.0	1	0.0	1	0.0
912-916	Blood Vessel Tumors	3	0.0	0	0.0	3	0.0
918-924	Osseous and Chrondromatous Neoplas	33	0.5	22	0.3	55	0.4
925	Giant Cell Tumors	11	0.2	6	0.1	17	0.1
926	Miscellaneous Bone Tumors	12	0.2	12	0.2	24	0.2
927-934	Odontogenic Tumors	3	0.0	1	0.0	4	0.0
938-948	Gliomas	285	4.2	160	2.1	445	3.1
949-952	Neuroepitheliomatous Neoplasms	6	0.1	7	0.1	13	0.1
953	Meningiomas	3	0.0	9	0.1	12	0.1
954-957	Nerve Sheath Tumors	7	0.1	4	0.1	11	0.1
958	Granular Cell Tumors	1	0.0	0	0.0	1	0.0
959	Malignant Lymphomas, Nos	278	4.1	148	2.0	426	3.0
965-966	Hodgkins Lymphoma	52	0.8	28	0.4	80	0.6
967-972	Non Hodgkins Lymphoma	60	0.9	31	0.4	91	0.6
973	Plasma Cell Tumors	76	1.1	43	0.6	119	0.8
980-994	Leukemias	221	3.2	147	2.0	368	2.6
998	Myelodysplastic Syndromes	0	0.0	2	0.0	2	0.0
Total	All Histologies	6831	100.0	7477	100.0	14308	100.0

Table 16: Number of Cancer Deaths by Age and Site (ICD10) with Percentages, Pune, 2006-10, Male

ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	99	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	1	0	1	2	1	0	2	0	7	0.3
C01-02	Tongue	0	0	0	0	0	1	0	11	11	6	7	15	10	6	10	9	0	86	3.1
C03-06	Mouth	1	1	0	0	0	1	3	7	14	12	24	25	27	28	18	13	0	174	6.3
C07-08	Salivary Gland	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	2	0	6	0.2
C09-10	Oropharynx	0	0	0	0	0	0	0	1	0	2	1	6	1	1	1	3	0	16	0.6
C11	Nasopharynx	0	0	0	2	0	1	0	0	0	1	0	0	0	0	1	0	0	5	0.2
C12-13	Hypopharynx	0	0	0	0	0	0	1	1	3	0	9	4	4	7	1	9	0	39	1.4
C14	Other Oral	0	0	0	0	0	0	0	0	2	1	4	0	3	3	0	1	0	14	0.5
C15	Oesophagus	0	0	0	0	1	1	4	7	4	6	13	23	25	34	29	70	1	218	7.9
C16	Stomach	0	0	0	0	0	5	3	4	7	9	12	25	23	27	25	41	0	181	6.6
C17	Small Intestine	0	0	0	0	0	0	0	1	1	1	0	1	0	2	2	0	0	8	0.3
C18	Colon	0	0	0	3	0	2	3	4	7	10	6	12	15	18	10	31	0	121	4.4
C19-21	Retum	0	0	0	0	0	3	5	4	1	7	7	6	11	14	13	19	0	90	3.3
C22	Liver	1	0	0	0	0	2	2	1	3	9	14	17	29	29	32	58	2	199	7.2
C23-24	Gall Bladder	0	0	0	0	0	1	2	3	1	0	0	3	5	8	7	5	0	35	1.3
C25	Pancreas	0	0	0	0	0	1	0	2	3	2	16	15	27	12	15	30	1	124	4.5
C26	Oth Dig Org	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	4	0.1
C30-31	Nose, Sinuse	0	0	0	0	1	0	1	2	1	1	1	0	3	2	1	3	0	16	0.6
C32	Larynx	0	0	0	0	0	1	0	0	8	7	9	18	22	18	9	30	0	122	4.4
C33-34	Lung	0	0	0	2	2	0	3	4	9	12	22	29	31	50	39	67	0	270	9.8
C37-38	Mediastinum, Plura	0	0	0	0	0	0	0	0	0	0	3	0	1	0	0	1	0	5	0.2
C40-41	Bone	0	0	1	7	4	1	1	0	0	1	0	4	3	0	0	2	0	24	0.9
C43	Skin Melanoma	0	0	0	1	0	0	0	0	1	0	1	0	0	0	1	0	0	4	0.1
C44	Skin Others	0	0	0	1	0	1	0	0	0	1	1	0	2	1	0	5	0	12	0.4
C47	Nervous System	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	2	0.1
C48	Retroperitonium	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.0
C49	Conn & Soft Tissue	1	0	0	0	2	1	0	1	0	1	1	1	1	3	2	4	0	18	0.7
C50	Breast	0	0	0	0	0	0	0	1	2	5	2	2	1	3	2	6	1	25	0.9
C60	Penis	0	0	0	0	0	0	0	0	0	1	2	2	1	4	1	2	0	13	0.5
C61	Prostate	0	0	0	1	0	0	0	0	0	1	1	8	19	26	49	120	1	226	8.2
C62	Testis	0	0	0	1	0	1	1	0	0	1	0	0	1	0	1	2	0	8	0.3
C64-65	Kidney	0	0	0	0	0	0	1	2	1	3	4	5	3	12	3	13	0	47	1.7
C66-68	Urinary Bladder	0	0	0	0	0	0	0	2	0	1	6	6	10	11	14	26	1	77	2.8
C69	Eye	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	4	0.1
C70-72	Brain	2	3	0	3	2	3	3	6	5	8	9	7	3	10	6	4	0		2.7
C73	Thyroid	0	0	0	0	0	0	0	0	0	0	1	2	2	2	1	2	1		0.4
C74-75	Other Endocrine Glan	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0		0.1
C76	Other III Def Sit	0	0	0	0	0	0	1	1	0	1	3	0	0	2	1	4	0	13	0.5
C77	Lymph Nodes	0	0	0	0	0	0	0	2	2	0	3	0	0	1	1	1	0	10	0.4
C78	Sec Resp & Dig	0	0	0	0	0	0	1	1	1	2	1	2	3	4	2	5	0	22	0.8
C79	Sec Others	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	2	0.1
C80	Unknown Primary	0	0	0	1	0	0	3	2	2	6	9	10	9	15	15	22	1	95	3.4
C81	Hodgkin Lymphoma	3	0	0	1	1	1	0	3	1	0	2	1	5	1	2	0	0	21	0.8
C82-85	N.H.Lymphoma	1	0	6	2	1	0	7	8	10	6	9	13	10	16	16	33	0	138	5.0
C90	Multiple Myeloma	0	0	0	0	0	0	0	0	2	0	4	6	2	5	6	5	0	30	1.1
C91	Lymphoid Leukemia	3	9	3	1	1	4	4	0	1	3	1	1	1	1	1	4	0	38	1.4
C92	Myeloid Leukemia	1	2	3	3	1	5	3	4	3	6	1	4	10	9	7	10	0	72	2.6
C93-95	Other Leukemia	0	2	1	2	0	1	0	4	2	1	2	1	5	1	5	2	0	29	1.1
Total	All Sites	14	18	14	31	18	37	52	90	110	136	213	275	332	391	351	668	9	2759	100.0

Table 17: Number of Cancer Deaths by Age and Site (ICD10) with Percentages, Pune, 2006-10, Female

ICD-10 SITE	0/
CO1-O2 Tongue	%
C03-06 Mouth	-
CO7-08 Salivary Gland	
C09-10 Oropharynx	
C11 Nasopharynx	
C12-13 Hypopharynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	_
C14	
C15	-
C16 Stomach 0 0 0 0 0 2 1 5 2 4 7 11 12 13 11 14 0 82 C17 Small Intestine 0 <t< td=""><td></td></t<>	
C17 Small Intestine	
C18	
C19-21 Return	_
C22 Liver 0 0 0 0 1 1 2 3 4 3 5 9 7 10 10 22 0 77 C23-24 Gall Bladder 0 0 0 0 0 0 0 1 2 0 3 6 5 7 7 6 16 0 5 C25 Pancreas 0	
C23-24 Gall Bladder 0 0 0 0 0 0 0 0 0 1 2 0 3 6 5 7 7 6 16 0 5 C25 Pancreas 0	2.3
C25 Pancreas 0 0 0 0 1 0 2 1 1 7 4 7 5 12 11 24 0 75 C26 Oth Dig Org 0 </td <td></td>	
C26 Oth Dig Org 0 <	
C30-31 Nose, Sinuse 0	2.7
C32	
C33-34 Lung	
C37-38 Mediastinum, Plura 0 0 0 0 1 0 0 1 0 0 0 2 1 1 0 6 C40-41 Bone 0 2 4 1 2 1 0 1 0 4 1 3 1 1 1 0 1 23 C43 Skin Others 0 <td></td>	
C40-41 Bone 0 2 4 1 2 1 0 1 0 4 1 3 1 1 1 0 1 23 C43 Skin Melanoma 0 <td></td>	
C43 Skin Melanoma 0	
C44 Skin Others 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 2 1 0 7 C48 Retroperitonium 0 0 0 0 0 0 0 0 1 1 0 1 2 0 0 6 C49 Conn & Soft Tissue 0 <th< td=""><td>0.8</td></th<>	0.8
C48 Retroperitonium 0 0 0 0 0 0 0 1 1 0 1 2 0 0 6 C49 Conn & Soft Tissue 0 0 0 1 1 0 2 1 2 1 0 2 4 1 0 16 C50 Breast 0 0 0 0 2 6 22 30 64 89 70 102 60 81 57 112 1 696 C51-52 Oth Fem Gen Org 0 0 0 0 0 0 0 1 1 0 0 1 3 1 2 6 0 15 15 2 1 3 1 2 6 4 7 13 11 0 4 2 3 3 2 2 8 33 2 3 3 2 2 <td>0.0</td>	0.0
C49 Conn & Soft Tissue 0 0 0 1 1 1 0 2 1 2 1 0 2 4 1 0 16 C50 Breast 0	0.2
C50 Breast 0 0 0 0 0 2 6 22 30 64 89 70 102 60 81 57 112 1 696 C51-52 Oth Fem Gen Org 0 0 0 0 0 0 0 1 1 0 0 0 1 3 1 2 6 0 15 C53 Cervix 0 0 0 0 0 0 0 1 1 1 0 0 0 1 3 1 2 6 0 15 C53 Cervix 0 0 0 0 0 0 0 0 1 1 1 0 1 2 6 4 7 13 11 0 46 C55 Uterus 0 0 0 0 0 0 0 1 1 1 0 1 2 6 4 7 13 11 0 46 C55 Uterus 0 0 0 0 0 0 0 1 1 2 3 3 2 3 3 5 5 0 27 C56 Ovary 0 0 0 0 0 2 2 2 7 8 13 24 19 42 29 32 27 49 2 256 C57-58 Oth Unsp Fem Gen Org 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 C64-65 Kidney 0 0 0 0 0 0 0 0 0 0 0 3 1 3 2 4 4 4 4 4 0 25 C66-68 Urinary Bladder 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 7 7 7 10 0 26 C69 Eye 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 7 7 7 10 0 26 C69 Eye 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 C70-72 Brain 2 2 1 3 1 2 2 1 3 1 6 9 5 6 1 5 0 50 C73 Thyroid 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 3 2 3 3 0 14 C74-75 Other Endocrine Gland 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0	0.2
C51-52 Oth Fem Gen Org 0 0 0 0 0 0 0 1 1 0 0 0 1 3 1 2 6 0 15 C53 Cervix 0 0 0 0 0 0 0 1 1 1 0 0 0 1 3 1 2 6 0 15 C53 Cervix 0 0 0 0 0 0 0 0 1 1 1 0 1 2 6 4 7 13 11 0 46 C55 Uterus 0 0 0 0 0 0 0 0 1 1 2 3 3 2 3 3 5 5 0 27 C56 Ovary 0 0 0 0 0 0 2 2 7 8 13 24 19 42 29 32 27 49 2 256 C57-58 Oth Unsp Fem Gen Org 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0	0.6
C53 Cervix 0 0 0 0 0 3 1 15 21 39 45 35 30 25 28 33 2 277 C54 Corpus Uteri 0 <	24.8
C54 Corpus Uteri 0 0 0 0 0 0 1 1 0 1 2 6 4 7 13 11 0 46 C55 Uterus 0 0 0 0 0 0 0 0 0 0 2 3 3 2 3 3 5 5 0 27 C56 Ovary 0 <t< td=""><td>0.5</td></t<>	0.5
C55 Uterus 0 0 0 0 0 0 0 1 2 3 3 2 3 3 5 5 0 27 C56 Ovary 0 0 0 0 0 2 2 7 8 13 24 19 42 29 32 27 49 2 256 C57-58 Oth Unsp Fem Gen Org 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 C64-65 Kidney 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 C66-68 Urinary Bladder 0 0 0 1 0 0 0 0 0 0 0 0 0 1 7 7 10 0 26 C69 Eye 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0	9.9
C56 Ovary 0 0 0 0 2 2 7 8 13 24 19 42 29 32 27 49 2 256 C57-58 Oth Unsp Fem Gen Org 0	
C57-58 Oth Unsp Fem Gen Org 0 <td>1.0</td>	1.0
C64-65 Kidney 0 <td< td=""><td>9.1</td></td<>	9.1
C66-68 Urinary Bladder 0 0 0 1 0	0.0
C69 Eye 0 <td>0.9</td>	0.9
C70-72 Brain 2 2 1 3 1 2 2 1 3 1 6 9 5 6 1 5 0 50 C73 Thyroid 0 0 0 0 0 0 1 0 1 1 0 3 2 3 3 0 14 C74-75 Other Endocrine Gland 0	0.9
C73 Thyroid 0 0 0 0 0 0 0 1 0 1 1 0 3 2 3 3 0 14 C74-75 Other Endocrine Gland 0	
C74-75 Other Endocrine Gland 0 </td <td>1.8</td>	1.8
C76 Other III Def Sites 0	0.5
C77 Lymph Nodes 0 0 0 0 1 0 0 0 1 0 <	
C78 Sec Resp & Dig 0 0 0 0 0 0 1 0 0 2 1 2 3 0 10 C79 Sec Others 0 0 0 0 0 0 0 1 0 2 1 2 3 0 1 0 12	0.2
C79 Sec Others 0 0 0 0 0 0 0 1 0 2 1 2 2 3 0 1 0 12	0.1
	0.4
	0.4
C80 Unknown Primary 0 0 1 1 0 0 0 2 6 5 6 6 5 8 8 13 2 63	2.2
C81 Hodgkin Lymphoma 0 0 0 0 0 1 0 1 2 0 1 2 1 0 2 1 0 11	0.4
C82-85 N.H.Lymphoma 0 1 1 0 0 5 1 1 4 3 6 6 7 11 10 11 0 67	2.4
C90 Multiple Myeloma 0 0 0 0 0 0 0 0 1 1 1 6 7 1 2 2 0 21	0.7
C91 Lymphoid Leukemia 1 2 2 2 4 1 2 1 2 2 2 0 1 1 3 3 0 29	1.0
C92 Myeloid Leukemia 3 3 3 2 2 4 2 4 2 5 5 8 3 7 4 4 0 61	2.2
C93-95 Other Leukemia 3 2 0 0 0 2 2 2 3 1 3 1 4 0 2 3 0 28	1.0
Total All Sites 9 12 12 10 21 39 61 110 174 252 276 344 297 327 327 523 10 2804	100.0

Table 18: Average Annual Age-Specific World Age Adjusted, Truncated (35-64) Cancer Death Rates per 100,000 Persons, Pune, 2006-10, Male

ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.7	0.5	0.0	1.2	0.1	0.1	0.2
C01-02	Tongue	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.2	1.3	0.9	1.3	4.2	3.6	2.7	6.5	5.6	0.7	0.9	1.9
C03-06	Mouth	0.1	0.1	0.0	0.0	0.0	0.1	0.3	0.7	1.7	1.8	4.3	7.0	9.8	12.8	11.8	8.1	1.4	2.0	3.7
C07-08	Salivary Gland	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.5	0.0	1.2	0.0	0.1	0.1
C09-10	Oropharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.2	1.7	0.4	0.5	0.7	1.9	0.1	0.2	0.4
C11	Nasopharynx	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0
C12-13	Hypopharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.0	1.6	1.1	1.4	3.2	0.7	5.6	0.3	0.4	0.7
C14	Other Oral	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.7	0.0	1.1	1.4	0.0	0.6	0.1	0.2	0.3
C15	Oesophagus	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.7	0.5	0.9	2.3	6.4	9.1	15.5	19.0	43.7	1.7	2.6	2.8
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.4	0.9	1.4	2.1	7.0	8.3	12.3	16.3	25.6	1.4	2.1	2.8
C17	Small Intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.0	0.3	0.0	0.9	1.3	0.0	0.1	0.1	0.1
C18	Colon	0.0	0.0	0.0	0.2	0.0	0.1	0.3	0.4	0.9	1.5	1.1	3.4	5.4	8.2	6.5	19.4	0.9	1.4	1.9
C19-21	Retum	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.4	0.1	1.1	1.3	1.7	4.0	6.4	8.5	11.9	0.7	1.0	1.2
C22	Liver	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.4	1.4	2.5	4.8	10.5	13.2	20.9	36.2	1.5	2.4	2.7
C23-24	Gall Bladder	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.1	0.0	0.0	0.8	1.8	3.7	4.6	3.1	0.3	0.4	0.4
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.3	2.9	4.2	9.8	5.5	9.8	18.7	1.0	1.5	2.4
C26	Oth Dig Org	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.7	1.2	0.0	0.1	0.0
C30-31	Nose, Sinuse	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.1	0.2	0.2	0.0	1.1	0.9	0.7	1.9	0.1	0.2	0.3
C32	Larynx	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	1.1	1.6	5.0	8.0	8.2	5.9	18.7	0.9	1.5	2.3
C33-34	Lung	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.4	1.1	1.8	3.9	8.1	11.2	22.8	25.5	41.8	2.1	3.2	3.8
C37-38	Mediastinum, Plura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.4	0.0	0.0	0.6	0.0	0.1	0.1
C40-41	Bone	0.0	0.0	0.1	0.5	0.3	0.1	0.1	0.0	0.0	0.2	0.0	1.1	1.1	0.0	0.0	1.2	0.2	0.2	0.3
C43	Skin Melanoma	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1
C44	Skin Others	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.2	0.0	0.7	0.5	0.0	3.1	0.1	0.1	0.2
C47	Nervous System	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C48	Retroperitonium	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0
C49	Conn & Soft Tissue	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.2	0.2	0.3	0.4	1.4	1.3	2.5	0.1	0.2	0.2
C50	Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.8	0.4	0.6	0.4	1.4	1.3	3.7	0.2	0.3	0.4
C60	Penis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.6	0.4	1.8	0.7	1.2	0.1	0.2	0.2
C61	Prostate	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	2.2	6.9	11.9	32.0	75.0	1.8	2.9	1.2
C62	Testis	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.7	1.2	0.1	0.1	0.1
C64-65	Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.5	0.7	1.4	1.1	5.5	2.0	8.1	0.4	0.6	0.6
C66-68	Urinary Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	1.1	1.7	3.6	5.0	9.2	16.2	0.6	0.9	0.9
C69	Eye	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C70-72	Brain	0.2	0.3	0.0	0.2	0.1	0.2	0.3	0.6	0.6	1.2	1.6	2.0	1.1	4.6	3.9	2.5	0.6	0.7	1.1
C73	Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.7	0.9	0.7	1.2	0.1	0.1	0.2
C74-75	Other Endocrine Glan	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0
C76	Other III Def Sites	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	0.9	0.7	2.5	0.1	0.1	0.1
C77	Lymph Nodes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.5	0.0	0.0	0.5	0.7	0.6	0.1	0.1	0.2
C78	Sec Resp & Dig	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.2	0.6	1.1	1.8	1.3	3.1	0.2	0.3	0.3
C79	Sec Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0
C80	Unknown Primary	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.2	0.2	0.9	1.6	2.8	3.3	6.9	9.8	13.7	0.7	1.1	1.3
C81	Hodgkin Lymphoma	0.3	0.0	0.0	0.1	0.1	0.1	0.0	0.3	0.1	0.0	0.4	0.3	1.8	0.5	1.3	0.0	0.2	0.2	0.4
C82-85	N.H.Lymphoma	0.1	0.0	0.5	0.1	0.1	0.0	0.6	0.9	1.2	0.9	1.6	3.6	3.6	7.3	10.5	20.6	1.1	1.5	1.8
C90	Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.7	1.7	0.7	2.3	3.9	3.1	0.2	0.4	0.5
C91	Lymphoid Leukemia			0.2	0.1	0.1	0.3	0.4	0.0	0.1	0.5	0.2	0.3	0.4	0.5	0.7	2.5		0.3	0.2
C92	Myeloid Leukemia				0.2				0.4	0.4	0.9	0.2	1.1	3.6	4.1	4.6	6.2		0.8	1.0
C93-95	Other Leukemia				0.1				0.4	0.2	0.2	0.4	0.3	1.8	0.5	3.3	1.2		0.3	
Total	All Sites	1.3	_		2.3	_	_	_	9.6	13.5		38.1	77.1	120.2	178.6				31.9	40.1

Table 19: Average Annual Age-Specific World Age Adjusted, Truncated (35-64) Cancer Death Rates per 100,000 Persons, Pune, 2006-10, Female

ICD-10	SITE	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	CR	AAR	TR
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.1
C01-02	Tongue	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.7	0.6	0.7	1.9	0.7	1.1	1.2	1.2	0.3	0.3	0.7
C03-06		0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.5	0.4	2.5	3.5	3.4	6.9	5.3	8.3	9.8	1.0	1.3	2.6
C07-08	Salivary Gland	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.6	0.6	0.0	0.1	0.1
	Oropharynx	0.0	0.0		0.0		0.0	_	0.1	0.0	0.3	0.0	0.9	0.0	0.0	0.0	0.6	0.1	0.1	0.2
	Nasopharynx	0.0	0.0		0.0		0.0	_	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.6	0.6	0.0	0.0	0.1
	Hypopharynx	0.0	0.0			0.0	0.0	_	0.1	0.1	0.3	0.4	0.0	1.0	0.0	1.2	0.0	0.1	0.1	0.3
C14	Other Oral	0.0	0.0			0.0	0.0	_	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.0
C15	Oesophagus	0.0	0.0			0.0	0.0	_	0.3	1.0	1.6	2.6	4.9	5.2	6.5	13.7	27.1	1.3	1.7	2.3
C16	Stomach	0.0	0.0			0.0	0.2	_	0.5	0.3	0.6	1.5	3.4	4.2	4.9	6.6	8.1	0.7	0.9	1.5
C17	Small Intestine	0.0	0.0	0.0		0.0	0.0	_	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.2	1.7	0.1	0.1	0.0
C18	Colon	0.0	0.0	0.0		0.1	0.3	0.1	0.1	0.9	0.6	1.5	1.5	3.8	3.0	9.5	15.0	0.8	1.0	1.2
	Retum	0.0	0.0			0.1	0.1	0.1	0.3	0.3	0.3	1.3	2.8	2.8	3.0	5.4	8.1	0.6	0.7	1.1
C22	Liver	0.0	0.0	0.0		0.1	-	0.2	0.3	0.6	0.5	1.1	2.8	2.4	3.8	6.0	12.7	0.7	0.9	1.1
C23-24	Gall Bladder	0.0	0.0	0.0			0.0	0.1	0.2	0.0	0.5	1.3	1.5	2.4	2.7	3.6	9.2	0.5	0.6	0.9
	Pancreas	0.0	0.0	0.0		0.1	0.0	_	0.1	0.1	1.1	0.9	2.2	1.7	4.6	6.6	13.8	0.6	0.8	0.9
C26	Oth Dig Org	0.0		0.0			0.0	_	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Nose, Sinuse	0.0	0.0				0.0		0.0	0.3	0.0	0.0	0.9	0.7	0.0	1.2	1.7	0.1	0.1	0.3
C32	Larynx	0.0	0.0	0.0		0.0		0.0	0.0	0.1	0.3	0.2	0.3	1.4	1.1	2.4	6.9	0.2	0.3	0.3
C33-34	Lung	0.0				0.0		0.3	1.2	1.3	1.1	4.8	6.2	6.6	8.4	13.1	18.5	1.5	1.9	3.1
	Mediastinum, Plura	0.0				0.0	-	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.6	0.6	0.1	0.1	0.0
	Bone	0.0	0.2	0.3		0.2	-	0.0	0.1	0.0	0.6	0.2	0.9	0.3	0.4	0.6	0.0	0.2	0.2	0.3
	Skin Melanoma	0.0	-	0.0		0.0	-	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Skin Others	0.0	0.0	0.0		0.0		0.0	0.0	0.0	0.2	0.2	0.0	0.3	0.4	1.2	0.6	0.1	0.1	0.1
	Retroperitonium	0.0	0.0			0.0		0.0	0.0	0.1	0.2	0.0	0.3	0.0	0.4	1.2	0.0	0.1	0.1	0.1
	Conn & Soft Tissue	0.0	0.0			0.1		0.1	0.0	0.3	0.2	0.4	0.3	0.0	0.8	2.4	0.6	0.1	0.2	0.2
	Breast	0.0	0.0			0.2		2.2	3.3	9.2	14.1	15.2	31.5	20.8	30.8	34.0	64.6	6.0	7.5	14.3
-	Oth Fem Gen Org	0.0	0.0				0.0	_	0.1	0.1	0.0	0.0	0.3	1.0	0.4	1.2	3.5	0.1	0.2	0.2
C53	Cervix	0.0	0.0			0.0	_	_	1.6	3.0	6.2	9.8	10.8	10.4	9.5	16.7	19.0	2.4	3.0	6.4
C54	Corpus Uteri	0.0	0.0	0.0	0.0	_		_	0.1	0.0	0.2	0.4	1.9	1.4	2.7	7.7	6.3	0.4	0.5	0.5
C55	Uterus	0.0			0.0			_	0.1	0.3	0.5	0.7	0.6	1.0	1.1	3.0	2.9	0.2	0.3	0.5
C56	Ovary	0.0			0.0	_		_	0.9	1.9	3.8	4.1	13.0	10.1	12.2	16.1	28.3	2.2	2.8	4.9
	Oth Unsp Fem Gen Or	0.0			0.0			_	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0
	Kidney	0.0			0.0			_	0.0	0.4	0.2	0.7	0.6	1.4	1.5	2.4	2.3	0.2	0.3	0.5
	Urinary Bladder	0.0	0.0						0.0	0.0	0.0	0.0	0.0	0.3	2.7	4.2	5.8	0.2	0.3	0.0
C69	Eye		0.0						0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0		
C70-72	-		0.2						0.1	0.4	0.2	1.3	2.8	1.7	2.3	0.6	2.9	0.4	0.5	0.9
C73	Thyroid		0.0						0.1	0.0	0.2	0.2	0.0	1.0	0.8	1.8	1.7	0.1	0.2	0.2
	Other Endocrine Gland		0.0						0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.6	0.6	0.0	0.0	
C76	Other III Def Sites		0.0						0.0	0.0	0.0	0.4	0.3	0.3	0.0	0.0	1.7	0.1	0.1	0.2
C77	Lymph Nodes		0.0						0.1	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.1
	Sec Resp & Dig		0.0						0.0	0.0	0.2	0.0	0.0	0.7	0.4	1.2	1.7	0.1	0.1	0.1
	Sec Others				0.0				0.1	0.0	0.3	0.2	0.6	0.7	1.1	0.0	0.6	0.1	0.1	0.3
C80	Unknown Primary				0.1				0.2	0.9	0.8	1.3	1.9	1.7	3.0	4.8	7.5	0.5	0.7	1.0
C81	Hodgkin Lymphoma		0.0						0.1	0.3	0.0	0.2	0.6	0.3	0.0	1.2	0.6	0.1	0.1	0.2
	N.H.Lymphoma		0.1						0.1	0.6	0.5	1.3	1.9	2.4	4.2	6.0	6.3	0.6	0.7	1.0
	Multiple Myeloma		0.0						0.0	0.1	0.2	0.2	1.9	2.4	0.4	1.2	1.2	0.2	0.3	0.6
C91	Lymphoid Leukemia	0.1			0.2				0.1	0.3	0.3	0.4	0.0	0.3	0.4	1.8	1.7	0.3	0.3	0.3
	Myeloid Leukemia		0.3						0.4	0.3	0.8	1.1	2.5	1.0	2.7	2.4	2.3	0.5	0.6	0.9
	Other Leukemia		0.2		_	_	_	_	0.2	0.4	0.2	0.7	0.3	1.4	0.0	1.2	1.7	0.2	0.3	0.5
	All Sites		1.3							24.9		60.0	106.4	103.0	124.4		301.8			51.6
rotai	, J.100	1.0	1.0		0.0		J. Z	U. 1	11.5		10.0	00.0	100.7	100.0	14 T. 7	107.0	501.0	2 7.0	00.0	01.0

APPENDIX

Calculation of rates and ratios

<u>Age specific rates</u> are calculated by dividing the number of cases in each 5 year age and sex stratum by corresponding population estimate for that stratum and multiplying the product by 100,000 to give the rates per 100,000.

<u>Crude rates</u> are calculated by the same way using total cancer cases and total cases and total population base by sex.

<u>Age adjusted rates</u> are calculated by summing the products of the age specific rates and the world standered population strata. They provide a rate which is independent of the age structure of the population of interest and are therefore useful in making comparisons between different populations, time periods etc.

<u>Cumulative rates</u> are calculated by multiplying the five year age specific rates per person by 5 and summing over age groups from 0-4 to 70-74. This rate is then expressed as a percentage. This rate is a good indicator of life time risk.